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Here, we review current evidence pointing to the function of VDAC1 in cell life and death,
and highlight these functions in relation to cancer. Found at the outer mitochondrial mem-
brane, VDAC1 assumes a crucial position in the cell, controlling the metabolic cross-talk
between mitochondria and the rest of the cell. Moreover, its location at the boundary
between the mitochondria and the cytosol enables VDAC1 to interact with proteins that
mediate and regulate the integration of mitochondrial functions with other cellular activi-
ties. As a metabolite transporter, VDAC1 contributes to the metabolic phenotype of cancer
cells. This is reﬂected by VDAC1 over-expression in many cancer types, and by inhibition of
tumor development upon silencingVDAC1 expression. Alongwith regulating cellular energy
production and metabolism, VDAC1 is also a key protein in mitochondria-mediated apop-
tosis, participating in the release of apoptotic proteins and interacting with anti-apoptotic
proteins. The involvement of VDAC1 in the release of apoptotic proteins located in the
inter-membranal space is discussed, as is VDAC1 oligomerization as an important step
in apoptosis induction. VDAC also serves as an anchor point for mitochondria-interacting
proteins, some of which are also highly expressed in many cancers, such as hexoki-
nase (HK), Bcl2, and Bcl-xL. By binding to VDAC, HK provides both metabolic beneﬁt and
apoptosis-suppressive capacity that offers the cell a proliferative advantage and increases
its resistance to chemotherapy. VDAC1-based peptides that bind speciﬁcally to HK, Bcl2,
or Bcl-xL abolished the cell’s abilities to bypass the apoptotic pathway. Moreover, these
peptides promote cell death in a panel of genetically characterized cell lines derived from
different human cancers. These and other functions point to VDAC1 as a rational target for
the development of a new generation of therapeutics.
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OVERVIEW
Research over the past decade has extended the prevailing view of
the mitochondrion to include functions well beyond the critical
bioenergetics role of supplyingATP to include cell signaling events,
inter-organellar communication, aging, cell proliferation, a target
in disease, and apoptosis. Mitochondria thus play a central role
in the regulation of apoptosis and serve as the venue for cellular
decisions leading to cell life or death. One of the mitochondrial
proteins controlling cell life and death is the voltage-dependent
anion channel (VDAC), also known as mitochondrial porin.
VDAC, located in the mitochondrial outer membrane, func-
tions as gatekeeper for the entry and exit of mitochondrial
Abbreviations: AIF, apoptosis-inducing factor; ANT, adenine nucleotide translo-
case; APAF-1, apoptosis protease-activating factor 1; Bcl-2, B cell lymphoma 2;
caspase, cysteinyl/aspartate-speciﬁc protease; CLL, chronic lymphocytic leukemia;
CyP D, cyclophilin D; Cyto c, cytochrome c; DIDS, 4,4′-diisothiocyanatostilbene-
2,2′-disulfonic acid; ER, endoplasmic reticulum; FNQs, furanonaphthoquinones;
G-6-P, glucose-6-phosphate; HK, hexokinase; IMM, inner mitochondrial mem-
brane; IP3Rs, inositol-1,4,5-trisphosphate receptors; LDH, lactate dehydrogenase;
MAC,mitochondrial apoptosis-inducing channel; NSCLC, non-small cell lung can-
cer; OMM, outer mitochondrial membrane; PDH, pyruvate dehydrogenase; PLB,
planar lipid bilayer; PT, permeability transition; PTP, permeability transition pore;
ROS, reactive oxygen species; RuR, ruthenium red; SR, sarcoplasmic reticulum; STS,
staurosporine; TNF-α, tumor necrosis factor alpha; TSPO, translocator protein;
UCP, uncoupling protein; VDAC, voltage-dependent anion channel.
metabolites, thereby controlling cross-talk between mitochondria
and the rest of the cell. VDAC is also a key player in mitochondria-
mediated apoptosis. Thus, in addition to regulating the metabolic
and energetic functions of mitochondria, VDAC appears to act
as a convergence point for a variety of cell survival and cell
death signals, mediated by its association with various ligands
and proteins. The focus of this review will be on the central
role of VDAC in cell life and death, addressing VDAC func-
tion in the regulation of mitochondria-mediated apoptosis, with
an emphasis on structure–function relationships. Understanding
VDAC structure–function relationships is critical for decipher-
ing how this channel can perform such a variety of functions, all
important for cell life and death. Finally, this review will also pro-
vide insight into VDAC function in Ca2+ homeostasis, protection
against oxidative stress, regulation of apoptosis, and involvement
in several diseases, as well as its role in the action of different
drugs.
VDAC: ISOFORMS, LOCATION, AND TRANSPORT ACTIVITY
VDAC ISOFORMS
In mammals, three homologous genes encode three VDAC iso-
forms, namely VDAC1, VDAC2, and VDAC3 (Shoshan-Barmatz
et al., 2010). The three proteins have similar molecular weights
(30–35 kDa), each shares approximately 70% identity, and all
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three can be found in most tissues, albeit in different amounts,
with themost abundant sub-type beingVDAC1 and the least com-
mon formbeingVDAC3 (CesarMde andWilson, 2004;Yamamoto
et al., 2006; De Pinto et al., 2010a; Shoshan-Barmatz et al., 2010;
Messina et al., 2012). VDAC1 and VDAC2 but not VDAC3 can
form a channel upon reconstitution into an artiﬁcial lipid bilayer,
with VDAC1 showing voltage-gated high conductance chan-
nel properties (see Channel Activity of VDAC1). VDAC2 also
presents normal gating activity, while VDAC3 does not insert
readily into membranes and generally does not gate well, even
at high membrane potentials (up to 80 mV; Sampson et al., 1997;
Xu et al., 1999).
The speciﬁc role of each VDAC isoform remains unclear,
although evidence indicates that they serve different physiologic
functions (Sampson et al., 1997; Xu et al., 1999; Wu et al., 1999).
For example, the absence of VDAC1 caused multiple defects in
respiratory complex activities in both skeletal and cardiac mus-
cle, while in VDAC3-deﬁcient mice, these defects are restricted
to the heart (Anﬂous-Pharayra et al., 2010), suggesting that in
vivo, these two isoforms fulﬁll distinct physiologic roles. In mice,
vdac1 and vdac2 deletion reduces respiratory capacity (Wu et al.,
1999), the absence of VDAC3 causes male sterility, and a lack
of both VDAC1 and VDAC3 causes inhibited growth (Samp-
son et al., 2001). Furthermore, it was demonstrated that VDAC1-
and VDAC3-lacking mice show deﬁcits in learning behavior and
synaptic plasticity (Weeber et al., 2002). VDAC3-lackingmicewere
male-infertile because their mitochondria and the axoneme of
their sperm are structurally altered (Sampson et al., 2001). Finally,
vdac1- and vdac3-deﬁcient mice are viable, whereas embryos
with a homozygous deletion of vdac2 die during development
(Cheng et al., 2003).
VDAC1 interacts with different proteins and factors, such as
hexokinase (HK; Abu-Hamad et al., 2008) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; Tarze et al., 2007), while
biochemical data indicate that VDAC1 but not VDAC2 binds HK
(Blachly-Dyson et al., 1993). This, however, has been questioned
(Azoulay-Zohar and Aﬂalo, 1999). Lately, it was demonstrated
that HK-I and VDAC3 exhibit a higher degree of mitochondrial
co-localization than does HK-I with either VDAC1 or VDAC2
(Neumann et al., 2010).
Large proteomic surveys and other studies have shown that
all three VDAC isoforms are subject to both phosphorylation
and acetylation at multiple sites (Distler et al., 2007; Wang et al.,
2008; Choudhary et al., 2009; Gauci et al., 2009; Menzel et al.,
2009; Kerner et al., 2012). Analysis of the amino acid sequence
of VDAC1 showed that the ﬁrst methionine is deleted, while the
second amino acid, an alanine, is acetylated (Kayser et al., 1989;
Gauci et al., 2009). Among the other post-translation modiﬁca-
tions VDAC1 undergoes are phosphorylation of serine, threonine,
and tyrosine residues (Distler et al., 2007; Kerner et al., 2012)
and acetylation of lysines (Kim et al., 2006; Schwer et al., 2009;
Zhao et al., 2010; Yang et al., 2011). Recently glycogen synthase
kinase 3 (GSK3)-mediated VDAC phosphorylation was reported,
allowing for control of outer mitochondrial membrane (OMM)
permeabilization in hepatosteatosis (Martel et al., 2012). Cur-
rently, the effects of these modiﬁcations on VDAC activity are
not clear.
VDAC LOCATION AND METABOLITE TRANSPORT
VDAC is localized to the OMM of all eukaryotes (Benz, 1994),
where it assumes a crucial position in the cell, serving as the
main interface between mitochondrial and cellular metabolisms.
VDAC is permeable to uncharged molecules up to ∼5,000 Da in
the open conﬁguration, mediating the ﬂux of ions, nucleotides
and other metabolites across the OMM (Shoshan-Barmatz et al.,
2010; Figure 1). In keeping with its two-way trafﬁcking role,
VDAC1 enables substrates, including pyruvate, malate, succi-
nate, and NADH, to enter the mitochondria and mediates the
exit of newly formed molecules, such as hemes (Shoshan-Barmatz
et al., 2010). Hence, down-regulation of VDAC1 expression results
in reduced metabolite exchange between mitochondria and the
cytosol, making VDAC1 essential for energy production and cell
growth (Abu-Hamad et al., 2006). Similarly, alterations in mito-
chondrial function are linked to VDAC closure, which limits the
normal ﬂow of metabolites in and out of mitochondria (Van-
der Heiden et al., 2000; Holmuhamedov and Lemasters, 2009).
VDAC1, at the OMM, is also involved in the entry and exit of Ca2+
(seeVDAC1 Transport of Ca2+ and Function in ER-mitochondria
Cross-talk). VDAC, furthermore, functions in cholesterol trans-
port across the OMM (Rone et al., 2009). Indeed, VDAC has
been proposed to be a necessary component of a protein com-
plex involved inmitochondrialmembrane cholesterol distribution
and transport and to play an important role in altered cholesterol
synthesis and transport in Morris hepatoma cells (Campbell and
Chan, 2008).
Given its location at the boundary between the mitochondria
and the cytosol, VDAC1 is able to interact with proteins that
mediate and regulate the integration of mitochondrial functions
with other cellular activities. VDAC1 interacts with HK and cre-
atine kinase to convert newly generated ATP into high-energy
storage forms, like glucose-6-phosphate (G-6-P) and creatine
phosphate, in brain and muscle, respectively. The over-expression
of VDAC1 in some cancer cells may be related to its multi-
functional activities, as required by high energy-demanding cells
(Shoshan-Barmatz and Golan, 2012; see VDAC Expression Levels
in Cancers and Enhancement by Pro-apoptotic Drugs).
Thus, VDAC is a dynamic regulator of global mitochondrial
function both in health and disease (Lemasters and Holmuhame-
dov, 2006).
EXTRA-MITOCHONDRIAL LOCALIZATION OF VDAC
VDAC1 was once thought to be localized solely to the OMM (Yu
and Forte, 1996). Indeed, although VDAC is present in abun-
dance in the OMM, various studies have revealed that VDAC
is also localized to cell compartments other than mitochondria
(Bathori et al., 2000; Shoshan-Barmatz and Israelson, 2005; De
Pinto et al., 2010b). VDAC, ﬁrst isolated from human plasma
membrane lymphocytes (Thinnes et al., 1989), was subsequently
detected in other cells of various tissues (Bathori et al., 2000;
De Pinto et al., 2010b). A splice variant of the mitochondrial
VDAC1 gene encoding a leader peptide of 13 amino acids at the
NH2 terminus was detected and termed plasmalemmal VDAC1
(pl-VDAC1; Buettner et al., 2000). The protein from this splice
variant exhibited extra-mitochondrial trafﬁcking to the endo-
plasmic reticulum (ER), the Golgi apparatus, and the plasma
Frontiers in Oncology | Molecular and Cellular Oncology November 2012 | Volume 2 | Article 164 | 2
“fonc-02-00164” — 2012/11/27 — 15:46 — page 3 — #3
Shoshan-Barmatz and Mizrachi VDAC in cell signaling and cancer
FIGURE 1 | Schematic representation ofVDAC1 as a multi-functional
channel and convergence point for a variety of cell survival and
cell death signals.The various functions of VDAC1 include control of
the metabolic cross-talk between the mitochondria and the rest of the
cell, cellular energy homeostasis by transporting ATP/ADP and NADH
between the inter-membrane space and the cytosol and by binding HK,
signaling by transporting Ca2+, ROS release to the cytosol and apoptosis,
both by binding to the apoptosis regulatory proteins, Bcl-2 family and HK.
Also presented are the Ca2+ inﬂux and efﬂux transport systems in the
outer and inner mitochondrial membranes and Ca2+-mediated regulation of
the tricarboxylic acid (TCA) cycle. The activation of pyruvate dehydrogenase
(PDH), isocitrate dehydrogenase (ICDH) and α-ketoglutarate
dehydrogenase (αKGDH) by intra-mitochondrial Ca2+, leading to
enhanced activity of theTCA cycle, is shown. The electron transport
chain (ETC) and the ATP synthase (FoF1) are also presented. VDAC in
the OMM is presented as a Ca2+ channel. In the IMM, the uptake of
Ca2+ into the matrix is mediated by a Ca2+-selective transporter, the
mitochondrial Ca2+ uniporter (MCU), regulated by a calcium-sensing
accessory subunit (MICU1). Ca2+ efﬂux is mediated by NCLX, a Na+/Ca2+
exchanger. High levels of matrix Ca2+ accumulation trigger the opening
of the PTP, a fast Ca2+ release channel. Molecular ﬂuxes are indicated
by arrows.
membrane (Gonzalez-Gronow et al., 2003; De Pinto et al., 2010b).
Caveolae and caveolae-like domains were shown to containVDAC
(Bathori et al., 1999). The extra-mitochondrial localization of
VDAC in bovine outer dense ﬁbers, a cytoskeletal component
of the sperm ﬂagellum, has been reported (Hinsch et al., 2004;
Triphan et al., 2008; Cassara et al., 2010). VDAC2 was shown to
be present in the membrane components of human spermato-
zoa (Liu et al., 2011). The presence of VDAC in the sarcoplasmic
reticulum (SR) of amphibian and mammalian skeletal muscle
and in the ER of rat cerebellum has also been demonstrated
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(Shoshan-Barmatz et al., 1996, 2004; Shoshan-Barmatz and Israel-
son, 2005).
The exact functions of the extra-mitochondrial VDAC are as
yet unknown. pl-VDAC1 was suggested to facilitate regulatory
volume decrease in epithelial cells and to play a role in cellular
ATP release and volume control (Okada et al., 2004). The possible
functions of VDAC in the SR/ER include providing a pathway for
transport of Ca2+, nucleotides and other metabolites across the
membrane, and involvement in apoptosis. The participation of
VDAC in supra-molecular complexes and intracellular commu-
nication, including calcium signal delivery between the ER and
mitochondria, has also been postulated (Shoshan-Barmatz and
Israelson, 2005; see VDAC1 Transport of Ca2+ and Function in
ER-mitochondria Cross-talk).
CHANNEL ACTIVITY OF VDAC1
VDAC CONDUCTANCE, ION SELECTIVITY, AND VOLTAGE-DEPENDENT
CHANNEL GATING
The channel properties of VDAC1 have been examined following
reconstitution of the puriﬁed protein into a planar lipid bilayer
(PLB). VDAC1 has been puriﬁed using various procedures and
detergents (Shoshan-Barmatz et al., 2010). Bilayer-reconstituted
VDAC1 assumes multiple voltage-dependent conformational
states, displaying different selectivities and permeabilities. VDAC1
shows symmetrical bell-shaped voltage-dependent conductance
with the highest conductance (4 nS at 1 M KCl) at low potentials
of −20 to +20 mV (Colombini, 1989; Benz, 1994; Figure 2). At
low potentials, when in the fully open state, VDAC1 selectively
conducts small ions (e.g., Cl−, K+, Na+), yet shows a preference
for anions, such as phosphate, chloride, adenine nucleotides, glu-
tamate, and other anionic metabolites, and large cations, such as
acetylcholine, dopamine, and Tris (Shoshan-Barmatz et al., 2010).
At higher positive ornegative potentials (>30–60mV), the channel
conductance is reduced and the selectivity shifts to small cations.
In this scenario, the channel becomes virtually impermeable to
ATP and ADP (Colombini, 1989; Benz, 1994; Shoshan-Barmatz
et al., 2010).
As a voltage-gated channel, VDAC1 must possess a voltage
sensor to respond to changes in transmembrane voltage. It is
believed that VDAC1 channels rely on two separate gating pro-
cesses, one that occurs at positive transmembrane potentials and
the other at negative potentials (Song et al., 1998). The N-terminal
α-helical segment of the channel has been proposed to act as
the voltage sensor, gating the pore via conformational changes
and/or movements (see The N-terminal Region of VDAC1:
Location, Translocation and Channel Gating). Clearly, the
molecular nature of VDAC1 gating mechanism has not yet been
resolved.
FIGURE 2 | Proposed three-dimensional structure ofVDAC1. (A) Side-view
of the X-ray crystal structure of mouse VDAC1 (Ujwal et al., 2008) in
a ribbon representation. The β-barrel is formed by 19 β-strands and the
N-terminal helix is folded into the pore interior. β-strands 1 and 19 are
parallel and colored blue. The C- and N-termini are annotated as C and N,
respectively. Loops and unstructured regions are colored green.
(B)Top-view of VDAC1 with the N-terminal inside the pore.
(C) VDAC1 in a proposed conformation with the N-terminal outside
the channel where it can interact with other proteins (PDB code:
3EMN).
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VDAC CHANNEL MODULATORS AND INHIBITORS
Despite the critical involvement of VDAC1 in various mitochon-
drial functions, little is knownof howVDAC is regulated. Accumu-
lated evidence suggests that VDAC1 function is modulated by var-
ious physiological ligands, such as glutamate, adenine nucleotides,
NADH, and non-physiological compounds, such as Koenig’s
polyanion, ruthenium red (RuR), dicyclohexylcarbodiimide
(DCCD), and 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid
(DIDS; Shoshan-Barmatz et al., 2006).
NADH was found to regulate the gating of mammalian, fun-
gal, and plant VDAC (Lee et al., 1994). For mammalian VDAC1,
molecular and biochemical evidence indicates that the protein
possesses one or more nucleotide-binding site(s) (Rostovtseva
et al., 2002; Yehezkel et al., 2006, 2007). Glutamate speciﬁcally,
but not aspartate or GABA, eliminates the bell shape of VDAC
voltage-dependence channel conductance (Gincel et al., 2000).
Accumulating evidence also suggests that VDAC possesses reg-
ulatory binding sites for Ca2+ (reviewed in Shoshan-Barmatz and
Gincel, 2003; Shoshan-Barmatz et al., 2006).
Various compounds targeting apoptotic cell death or cell pro-
liferation were found to mediate their activity via interaction with
VDAC1, modulating VDAC1 activity (see VDAC as a Pharma-
cological Target for Compounds Affecting Cell Proliferation or
Apoptosis). In addition, VDAC1, acting as a docking site for
various proteins, is regulated via protein–protein interactions.
Speciﬁcally, HK, Bcl2, Bcl-xL, actin, and tubulin were found
to interact with VDAC1 and alter its channel conductance (see
VDAC1 Association with Proteins and Cancer).
Finally, high cholesterol, known to reduce the activity of
membrane-associated proteins, was found to inhibit channel
conductance and the metabolic function of VDAC (Campbell and
Chan, 2008). It has also been reported that plantVDAC undergoes
a reversible regulation of selectivity and voltage-dependence in the
presence of sterols (Mlayeh et al., 2010).
VDAC STRUCTURE–FUNCTION RELATIONSHIPS
Since their discovery in the mid-1970s, great efforts have been
devoted to understanding structure–function relationships of
VDACs using numerous techniques, including circular dichro-
ism (CD), atomic force microscopy (AFM), electron microscopy,
NMR, crystallography, and others.
THE THREE-DIMENSIONAL STRUCTURE OF hVDAC1
VDAC1 is a polypeptide of 283 amino acids with Met1 missing
in the mature protein (Thinnes et al., 1989; Blachly-Dyson et al.,
1993). Various studies have led to the development of models pos-
tulating the transmembrane organization of VDAC1, comprising
a single α-helix at the N-terminus and 13, 16, or 19 transbilayer
β-strands that form a β-barrel (De Pinto et al., 1991; Song et al.,
1998; Casadio et al., 2002; Colombini, 2004).
Recently, the 3D structure of recombinant VDAC1 was solved
using X-ray crystallography, NMR and a combination of the
two. Such studies presented VDAC1 as composed of 19 β-strands
arranged as a barrel, with strands β1 and β19 being in paral-
lel conformation (Figure 3; Bayrhuber et al., 2008; Hiller et al.,
2008; Ujwal et al., 2008). The N-terminal domain of VDAC1,
consisting of 25 amino acids, was shown to be very dynamic
and possesses different degrees of α-helical content in each of
the three proposed structures (Bayrhuber et al., 2008; Hiller
et al., 2008; Ujwal et al., 2008). All three methods employed
FIGURE 3 | Channel properties of bilayer-reconstituted purifiedVDAC1.
Bilayer-reconstituted VDAC single and multi-channel activity was assayed
as described previously (Gincel et al., 2000). Puriﬁed VDAC (1–5 ng) was
reconstituted into a PLB. In (A), a typical activity recording of VDAC
incorporated into a PLB is presented as current traces obtained in response
to voltage steps from 0 mV to either −10 or −60 mV. In symmetric solution
(1 M NaC), when the voltage was changed from −0 to 10 mV, the channel
opens and remains stable in this conformation for up to 2 h. However, when
the voltage was changed from 0 to −60 mV, the current ﬁrst increased, due
to a greater driving force. However, within less than 1 s, channel
conductance decreased and VDAC assumed multiple conductance states. The
dashed line indicates the zero current level, while the sub-states of the
channel are indicated by arrowheads. In (B), Multi-channel recordings of the
average steady-state conductance of VDAC are presented as a function of
voltage. The conductance (Go ) at a given voltage was normalized to the
conductance at −10 mV (Gmax). Each point is the average of three
experiments. This voltage-dependent behavior is well known for
VDAC.
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refolded recombinant VDAC1 expressed in E. coli and puriﬁed
from inclusion bodies. As such, it has been argued that the
refolding conditions employed led to the appearance of non-
native structures, as biochemical andbiophysical approaches argue
for the existence of additional extra-membranal VDAC regions
(Colombini, 2009).
The pore diameter of the channel has been estimated to be
between 3 and 3.8 nm, based on biochemical and structural meth-
ods (Colombini, 1980; Goncalves et al., 2007; Bayrhuber et al.,
2008) and about 1.5 nm when the N-terminal α-helix is located
inside the channel, according to the recent 3D studies (Bayrhu-
ber et al., 2008). Finally, there is evidence that cholesterol is
bound to mammalian mitochondrialVDAC and sterols seem to be
important for the folding of VDAC (De Pinto et al., 1989; Hiller
et al., 2008).
THE N-TERMINAL REGION OF VDAC1: LOCATION, TRANSLOCATION,
AND CHANNEL GATING
The location of the N-terminal region of VDAC1 with respect to
the pore, its role in voltage-gating and its interaction with associ-
ated proteins have been the focus of intensive study, as described
below.
Location and translocation of the N-terminal region
The VDAC N-terminal region was proposed to lie on the mem-
brane surface (Reymann et al., 1995), to be exposed to the
cytoplasm (De Pinto et al., 2003) or to cross the membrane
(Colombini, 2004). The 3D structures of recombinant VDAC1,
however, revealed that the N-terminal domain is located inside
the channel pore, causing a partial obstruction of the wide pore,
possibly providing structural reinforcement to the channel walls
(Bayrhuber et al., 2008; Hiller et al., 2008; Ujwal et al., 2008;
Schneider et al., 2010; Figure 3). Deletion of the N-terminal heli-
cal domain did not affect the correct mitochondrial targeting of
the protein (De Pinto et al., 2007).
Various studies suggesting that the N-terminal region of
VDAC1 constitutes a mobile component of the protein (see
VDAC1 N-terminal Domain Function in Voltage-gating and Cell
Death). In 2D crystals of Neurospora crassaVDAC1, oblique arrays
of the N-terminal domain appear to extend laterally from the bar-
rel, into the aqueous phase (Guo et al., 1995). The N-terminus of
the protein was shown to be accessible to anti-VDAC1 antibodies
raised against this part of the protein (Guo et al., 1995; Shoshan-
Barmatz et al., 2004; Abu-Hamad et al., 2006). The same domain
is exposed to kinases, as threonine-13 undergoes phosphoryla-
tion (Distler et al., 2007). Additionally, the N-terminal domain
of VDAC1 interacts with cytosolic proteins and acts as a recruit-
ing site for HK1, Bcl2, and Bcl-xL and thus is a key structural
feature mediating VDAC interaction with anti-apoptotic proteins
to enable their function (Shi et al., 2003b; Abu-Hamad et al.,
2009; Arzoine et al., 2009; Arbel and Shoshan-Barmatz, 2010),
suggesting that this VDAC region is exposed outside the pore.
Finally, a recent in silico study supports the role of the N-terminal
in controlling shape and permeability of the channel. In the
absence of N-terminal, increased overall β-barrel motion, result-
ing in elliptic, semi-collapsed barrel shapes, is seen (Zachariae
et al., 2012).
Taken together, these ﬁndings suggest that the N-terminal
region of VDAC1 is loosely attached to the barrel wall and
can undergo translocation to become exposed at the membrane
surface. This movement allows VDAC1 to interact with the anti-
apoptotic proteins, HK, Bcl-xL, and Bcl2, and may participate
in VDAC1 oligomerization. The signal and nature of conforma-
tional changes inducing VDAC1 N-terminal region translocation,
both under physiological and apoptotic conditions, await further
study.
VDAC1 glycine-rich sequence
It was reported that inVDAC1, a glycine-rich sequence (GXXXG),
highly conserved inmammals, connects theN-terminal domain to
the β-barrel, thus providing the ﬂexibility needed for N-terminal
translocation in and out of the pore (Geula et al., 2012a). When
this ﬂexible region is mutated by replacing glycines with prolines,
the N-terminal region favors a location out of the pore, thereby
affecting channel gating. Moreover, in such mutants, the abil-
ity to form VDAC1 dimers was highly increased. The GXXXG
motif has been linked with dimerization in proteins such as gly-
cophorin A (Gerber and Shai, 2001), human carbonic anhydrase
(Whittington et al., 2001), yeast ATP synthase (Saddar and Stu-
art, 2005), carnitine palmitoyltransferase (Jenei et al., 2009, and
others). In VDAC1, this motif is not required for VDAC1 dimer-
ization but may be involved in interaction withVDAC1-associated
proteins (Geula et al., 2012a). Interestingly, such a motif in Bcl-xL,
interacting with VDAC1 (Arbel et al., 2012), has been recently
suggested to mediate VDAC interaction with other proteins
(Ospina et al., 2011).
VDAC1 N-terminal domain function in voltage-gating and cell death
It was reported that during voltage-gating or interaction with
molecules, such as cytochrome c (Cyto c), some motion of VDAC
occurred (Stanley et al., 1995). N-terminal-truncated mV DAC1
was shown to exhibit high conductance at all tested voltages and
was proposed to be a main effector in those apoptotic events
dependent on VDAC1 (De Pinto et al., 2008; Abu-Hamad et al.,
2009). Using recombinant mutated VDAC1 with the N-terminal
cross-linked to channel wall, it was shown that voltage-gating was
modiﬁed but not completely lost (Teijido et al., 2012). On the
other hand, mobility of the N-terminal region and the contri-
bution of this domain to channel gating and interaction with
anti-apoptotic proteins were recently demonstrated using site-
directed mutagenesis and cysteine substitution, together with a
thiol-speciﬁc cross-linker (Geula et al., 2012a). Swapping the N-
terminal domain of VDAC1 and with that of VDAC3 restores full
activity of the channel (Reina et al., 2010).
Different models for the voltage-dependent gating of VDAC1
via the N-terminal region have been proposed: (i) Blockage of the
pore by movement of the N-terminal domain within the lumen
from the barrel wall toward the center of the channel (Hiller
et al., 2008; Ujwal et al., 2008); (ii) transition of the N-terminal
region from an α-helical structure that aligns with the barrel wall
to a less-structured, unfolded helix element that interacts with
the opposing barrel wall (Bayrhuber et al., 2008; Summers and
Court, 2010), and (iii) movement of the N-terminal region into
and out of the channel lumen (De Pinto et al., 2008; Abu-Hamad
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et al., 2009; Geula et al., 2012a; Teijido et al., 2012). Calcula-
tions using both Poisson–Boltzmann and Poisson–Nernst–Planck
electrostatic equations agree with the N-terminal region being
involved in gating but not via lateral or horizontal movement of
the helix (Choudhary et al., 2010). Thus, the accumulated results
and the derived models point to the N-terminal domain as being
involved in the channel gating, although the precise mechanism
has yet to be described.
VDAC1 C-terminal domain
In contrast to the extensive studies directed at deﬁning N-
terminal domain structure–function, very little research effort has
addressed the VDAC1 C-terminal domain. Recently, a frame-shift
resulting in appearance of an early stop codon in theVDAC1 gene,
leading to the absence of approximately 60% of the C-terminal
portion of VDAC1, was noted in gastric and colonic cancers
with microsatellite instability (Yoo et al., 2011). Patients with this
somatic mutation are heterozygous (Yoo et al., 2011).
A link between the VDAC1 C-terminal region and cancer also
comes from studies connecting hypoxia and C-terminal cleavage
(Brahimi-Horn et al., 2012). Hypoxic conditions were found to
trigger cleavage of the VDAC1 C-terminal to yield a 26-kDa pro-
tein (Brahimi-Horn et al., 2012). This C-terminal-cleavedVDAC1
was regulated by HIF-1α and was correlated with hypoxic cell sur-
vival and chemotherapy resistance (Brahimi-Horn et al., 2012).
Based on the incidence of ΔC-VDAC1 in lung cancer (about 50%
on average and higher in late stage tumors), this form of the
protein was proposed to serve as a biomarker to stratify tumor
progression in lung cancer patients (Brahimi-Horn et al., 2012).
Finally, it was reported that an unidentiﬁed mitochondrial cal-
pain cleaves the apoptotic induction factor (AIF) and VDAC1
in a Ca2+-dependent manner, and that such cleavage triggers
tVDAC–Bax pores that are associated with the release of tAIF
(Ozaki et al., 2009).
VDAC1 OLIGOMERIZATION AND FUNCTION
Puriﬁed and membrane-embedded mammalian VDAC1 were
shown to assemble into dimers, trimers, tetramers, and higher
oligomers, as revealed by chemical cross-linking and ﬂuorescence
resonance energy transfer (FRET) analysis (Zalk et al., 2005).
A low-resolution (15 Å) surface structure of VDAC1, obtained
by metal shadowing and cryo-electron microscopy of human
VDAC1 crystals grown in the presence of phospholipids, showed
a dimeric organization of VDAC1 (Dolder et al., 1999). High-
resolution AFM of puriﬁed native OMM from potato tubers
(Hoogenboomet al., 2007) or yeast (Goncalves et al., 2007) showed
the distribution of VDAC in an equilibrium ranging from sin-
gle membrane-embedded pores to hexamers and higher-order
oligomers (Hoogenboom et al., 2007), including arrays of up to
20 molecules (Goncalves et al., 2007). In addition, the use of
symmetry operators on the NMR-based structure of recombinant
hVDAC1 implied that it forms a dimer of monomers arranged in
parallel (Bayrhuber et al., 2008), while analysis of the crystal pack-
ing of mVDAC1 revealed strong anti-parallel dimers that further
assemble into hexamers (Ujwal et al., 2009).
Interestingly, VDAC1 oligomerization is highly increased
upon apoptosis induction (Keinan et al., 2010). Structural and
computational-based approaches, in combination with site-
directed mutagenesis, cysteine replacement, and chemical cross-
linking, identiﬁed the contact sites between VDAC1 molecules in
dimers and higher oligomers (Geula et al., 2012b). Two forms of
dimeric VDAC1, one with a contact site involving β-strands 1, 2,
and 19 and the second involving β-strands 16 and 17, were iden-
tiﬁed. Moreover, the results suggest that VDAC1 exists as a dimer
that undergoes conformational changes upon apoptosis induc-
tion to assemble into higher oligomeric states with contact sites
also involving β-strand 8 (Geula et al., 2012b).
The function of VDAC1 oligomers is not known. It was pro-
posed that an organization of VDAC1 beyond the monomeric or
dimeric forms may contribute to stabilizing the protein (Ujwal
et al., 2009). On the other hand, it was proposed that the
oligomeric assembly of VDAC1 offers a platform for other pro-
teins to oligomerize, such as HK (Zalk et al., 2005). HK-I assumes
a tetrameric structure that is greatly enhanced when the enzyme is
bound to mitochondria (Xie and Wilson, 1990) or when it inter-
acts with the mitochondria to inhibit permeability transition pore
(PTP)opening (Azoulay-Zohar et al., 2004). Creatine kinase,when
bound to VDAC1 at the inter-membrane space, forms high order
oligomers (Brdiczka et al., 1994; Stachowiak et al., 1998), inter-
acting with VDAC1 exclusively in the octameric state, with the
dimeric state only showing weak afﬁnity for VDAC1 (Schlattner
et al., 2001).
Recently, the function of VDAC1 oligomerization in apop-
tosis, namely mediating the pathway for the release of Cyto c,
was proposed (Zalk et al., 2005; Shoshan-Barmatz et al., 2006,
2008b; Abu-Hamad et al., 2009; Keinan et al., 2010). VDAC1
oligomerization was strongly correlate with apoptosis induction
(Shoshan-Barmatz et al., 2008b, 2009; Abu-Hamad et al., 2009;
Keinan et al., 2010), while apoptosis induction by various induc-
ers was accompanied by an up to 20-fold increase in VDAC1
oligomerization, indicating a shift in VDAC1 organization toward
the oligomeric form under such conditions (Shoshan-Barmatz
et al., 2008b; Keinan et al., 2010; see VDAC1 Oligomerization and
Release of Cytochrome c).
VDAC1 AND MITOCHONDRIA-MEDIATED APOPTOSIS
In apoptosis, a multi-step process that can be initiated by a variety
of stimuli, a cascade of cysteine proteases, caspases, are acti-
vated, subsequently leading to organized cell demise. Defects
in the regulation of apoptosis are often associated with various
diseases, with the ability of cells to evade apoptosis being a hall-
mark of cancer (Hanahan and Weinberg, 2000). Alterations of
apoptosis are involved in tumorigenesis, as well as in cellular
responses to anti-tumor treatments (Hickman, 2002; Johnstone
et al., 2002).
THE EXTRINSIC AND INTRINSIC APOPTOTIC PATHWAYS
Apoptosis can be activated via the extrinsic or intrinsic path-
ways. In the extrinsic pathway, apoptosis is induced by extrinsic
apoptotic signals initiated by ligand engagement of cell surface
receptors, such as Fas and TNF receptors. The intrinsic path-
way is initiated in mitochondria in response to different stimuli
(Green and Evan, 2002; Johnstone et al., 2002; Chowdhury et al.,
2006). Receptor binding by an extrinsic signal typically leads to the
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recruitment of adapter proteins that promote caspase oligomer-
ization and auto-processing. The extrinsic apoptotic pathway can
induce activation of the intrinsic pathway via caspase 8-dependent
cleavage of Bid and translocation of the truncated form (tBid)
to the mitochondria (Korsmeyer et al., 2000; Yin, 2000). Thus,
apoptotic signals initiated by death receptors can be linked to
mitochondria-mediated apoptosis.
The intrinsic apoptotic pathway involves mitochondria. Mito-
chondria contain an arsenal of apoptogenic factors, normally
residing in the inter-membranal space (IMS), such as Cyto c,
AIF, Smac/DIABLO, and endonuclease G. During transduction
of an apoptotic signal into the cell, an alteration in mitochon-
drial permeability occurs, causing the release of these apoptogenic
factors from the IMS (Green and Evan, 2002; Chowdhury et al.,
2006; Shoshan-Barmatz et al., 2010). These proteins participate
in complex processes resulting in the activation of proteases and
nucleases, leading to protein and DNA degradation, and ulti-
mately, cell death. Most notable among the released protein is Cyto
c that initiates apoptosis by binding to a central apoptotic regula-
tor,Apaf-1, promoting oligomerization of Apaf-1 and activation of
caspase 9, which subsequently activates effector caspases, such as
caspases 3, 6, and 7, encouraging execution of cell death. HowCyto
c and other apoptogenic factors are released from mitochondria is
not clear, and will be discussed below.
Mitochondria-mediated apoptosis can be induced in response
to different stimuli (Costantini et al., 2000), including high levels
of cytoplasmic Ca2+, reactive oxygen species (ROS), activation of
pro-apoptotic Bcl-2 family proteins (Le Bras et al., 2005; Keeble
and Gilmore, 2007; Kroemer et al., 2007) or UV damage (Denning
et al., 2002). Chemotherapeutic agents act via different mecha-
nisms to induce mitochondria-dependent apoptosis (Costantini
et al., 2000). These include betulinic acid (Fulda et al., 1998),
PK11195 (Hirsch et al., 1998), diamide (Zamzami et al., 1998),
lonidamine (LND; Ravagnan et al., 1999), arsenite (Larochette
et al., 1999), 6[3-adamantyl-4-hydroxyphenyl]-2-naphthalene
carboxylic acid (CD437; Marchetti et al., 1999), 2-chloro-2′-
deoxyadenosine, 2-chloro-2′-ara-ﬂuorodeoxy-adenosine (Genini
et al., 2000), MT-21 (Watabe et al., 2000), verteporﬁn (Belzacq
et al., 2001), resveratrol (Tinhofer et al., 2001), and paclitaxel
(Andre et al., 2000).
As mitochondria represent an appropriate target for therapeu-
tic agents designed tomodulate apoptosis, continued research into
the mechanisms of mitochondria-mediated apoptotic cell death,
coupled with further characterization of the released molecules,
will offer new and promising targets for chemotherapeutic inter-
vention in a host of pathologies.
VDAC1 AND APOPTOSIS
The involvement of VDAC1 in mitochondria-mediated apopto-
sis has been proposed based on several lines of experimental
evidence: (a) Anti-VDAC1 antibodies speciﬁcally and effectively
prevent As2O3-induced Cyto c release from isolated mitochondria
(Zheng et al., 2004) and when microinjected into cells, prevented
Bax-induced Cyto c release and subsequent apoptosis, as well as
etoposide-, paclitaxel-, and staurosporine (STS)-induced apopto-
sis (Shimizu et al., 2001). Anti-VDAC1 antibodies also inhibited
the interaction of Bax with VDAC and the triggering of cell death
(Madesh and Hajnoczky, 2001; Shimizu et al., 2001; Zheng et al.,
2004). Microinjection of anti-VDAC antibodies into primary rat
hepatocytes effectively prevents apoptosis and Bax–VDAC inter-
actions, as induced by ethanol (Adachi et al., 2004); (b) VDAC1
is the proposed target of pro- and anti-apoptotic members of
the Bcl2 family and of HK-I and HK-II (Shimizu et al., 2001;
Shi et al., 2003b; Azoulay-Zohar et al., 2004; Zaid et al., 2005;
Arbel and Shoshan-Barmatz, 2010; see VDAC1 Transport of
Ca2+ and Function in ER-mitochondria Cross-talk); (c) inhibi-
tion of Cyto c release and cell death mediated by HK occurred
in cells expressing native but not mutated VDAC1 (Zaid et al.,
2005; Abu-Hamad et al., 2008; Arzoine et al., 2009); (d) RuR,
interacting with Ca2+-binding proteins, interacts with native but
not mutated VDAC1 to prevent Cyto c release and cell death
(Zaid et al., 2005; Israelson et al., 2008); (e) siRNA-mediated
down-expression of VDAC1 prevented cell death and activation
of Bax induced by cisplatin and strongly reduced cisplatin-
induced release of Cyto c and AIF, as well as the maturation of
caspases-3 (Tajeddine et al., 2008). Similarly, reducing VDAC1
expression by siRNA attenuated endostatin-induced apoptosis
(Yuan et al., 2008); (f) over-expression of human, murine, yeast,
and rice VDAC induce apoptotic cell death (Godbole et al., 2003;
Zaid et al., 2005; Abu-Hamad et al., 2008); (g) knockdown of
VDAC1 in non-small cell lung cancer (NSCLC) cells inhibited
TRAIL-induced activation of caspase-8 and subsequent apopto-
sis (Chacko et al., 2010); and (h) release of Cyto c was obtained
using puriﬁed VDAC1 reconstituted into liposomes in which
Cyto c had been encapsulated (Madesh and Hajnoczky, 2001;
Zalk et al., 2005). Finally, (i) growth factor removal from the
medium resulted in reduced nucleotide exchange between mito-
chondria and cytosol, leading to Cyto c release and apoptosis
(Vander Heiden et al., 2000).
In general, there are two views as to the relationship between
the conducting state of the VDAC1 channel and cell death. While
one view suggests that closure, rather than opening of VDAC leads
to OMM permeabilization and apoptosis (Vander Heiden et al.,
2000), the second model suggest a distinct VDAC1-based con-
ducting pathways, namely a pore formed in the center of aVDAC1
oligomer (Shimizu et al., 1999; Zalk et al., 2005; Shoshan-Barmatz
et al., 2006; see VDAC1 Oligomerization and Function).
PROPOSED MECHANISMS OF CYTOCHROME c RELEASE FROM THE
MITOCHONDRIA
Several proposals regarding the mechanism of Cyto c crossing
the OMM have been proposed (Figure 4). However, none of the
current models of mitochondrial membrane permeabilization can
account for all of the experimental data.
In healthy cells, Cyto c is located in the mitochondrial IMS,
where it serves as an electron shuttle between complexes III and
IV of the respiratory chain, with most Cyto c being bound to
cardiolipin (CL). Signals inducing mitochondria-mediated apop-
tosis result in the release of IMS proteins, including Cyto c (see
The Extrinsic and IntrinsicApoptotic Pathways). Themechanisms
by which Cyto c and other pro-apoptotic effector molecules are
released have challenged many researchers and several competing
models have been proposed to explain the workings of this event
(Figure 4; Shoshan-Barmatz et al., 2008a). While some models
Frontiers in Oncology | Molecular and Cellular Oncology November 2012 | Volume 2 | Article 164 | 8
“fonc-02-00164” — 2012/11/27 — 15:46 — page 9 — #9
Shoshan-Barmatz and Mizrachi VDAC in cell signaling and cancer
FIGURE 4 | Schematic representation of proposed models for the
release of apoptogenic proteins from the mitochondrial inter-membrane
space mediating the mitochondrial death decision. Different models
explaining how OMM permeability changes during apoptosis induction,
allowing the release of apoptogenic factors, such as Cyto c. (A) A
permeability transition pore (PTP) provides the apoptogenic proteins release
pathway. It is proposed that a large conductance pore-forming complex, the
PTP, composed of VDAC at the OMM, ANT at the IMM and CypD in the
matrix, allows apoptogenic protein release. (B) VDAC closure and OMM
rupture serves as the cytochrome c release pathway. Prolonged VDAC closure
leads to mitochondrial matrix swelling, OMM rupture, and hence, the
appearance of a non-speciﬁc release pathway for apoptogenic proteins.
(C) Bax activation followed by its oligomerization resulting in OMM
permeabilization. Upon apoptosis induction, Bax became associated with
mitochondria as a large oligomer/complex, forming a Cyto c-conducting
channel in the OMM. (D) A pore formed by oligomerized forms of Bax and
Bak after their activation by tBID. BH3-only proteins (e.g., Bid) induce
oligomerization of Bax/Bak on the OMM, resulting in Bax activation and OMM
permeabilization. (E) MAC as the release pathway. The mitochondrial
apoptosis-induced channel, MAC, is a high-conductance channel that
forms during early apoptosis and is a putative cytochrome c release
channel. MAC formation occurs without loss of outer membrane integrity
and depolarization. Members of the Bcl-2 family of proteins regulate
apoptosis by controlling the formation of MAC. (F) A Bax- and VDAC-based
hetero-oligomer mediates cytochrome c release. The interaction of
pro-apoptotic proteins (Bax/Bak) with VDAC forms a cytochrome c release
pathway. (G) A lipid channel formed by the lipid, ceramide. Ceramides were
shown to induce apoptosis via direct action on mitochondria. A self-
assembled ceramide channel is proposed to act as the apoptotic protein
release pathway. (H) Oligomeric VDAC1 as a channel for the release of
apoptotic proteins. A protein-conducting channel is formed within a VDAC1
homo-oligomer. VDAC1 oligomerization thus functions in mitochondria-
mediated apoptosis (see VDAC1 Oligomerization and Release of Cytochrome
c). The dynamic equilibrium between VDAC monomeric and oligomeric states
can be regulated by various factors, such as Ca2+, oxidative stress and
cytochrome c.
suggest that the proteins crossing the OMM exclusively involve an
increase in OMM permeability due to the formation of a chan-
nel large enough to allow for the release of proteins, such as Cyto
c, others consider efﬂux of the proteins to be due to disruption
of OMM integrity. The following brieﬂy describes the various
proposed models:
The permeability transition pore and the release of pro-apoptotic
proteins
One model (Model A, Figure 4) for mitochondrial mem-
brane permeability (MMP) suggests the formation of a PTP,
a large high-conductance multi-protein complex comprising
several components and spanningbothmitochondrialmembranes
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(Bernardi, 1999; Lemasters et al., 1999; Halestrap and Green,
2000; Shoshan-Barmatz andGincel, 2003; Tsujimoto and Shimizu,
2007). PTP opening is followed by Ca2+ accumulation in the
matrix, leading to a sudden increase in permeability to solutes
(up to 1,500 Da; Bernardi, 1999; Lemasters et al., 1999; Halestrap
and Green, 2000; Shoshan-Barmatz and Gincel, 2003; Tsujimoto
and Shimizu, 2007). This Ca2+-dependent increase in MMP leads
to loss of membrane potential, mitochondrial swelling, and rup-
ture of the OMM. According to this model, other factors, such
as changes in the energetic balance of the mitochondria, anoxia,
and ROS can also induce MMP due to PTP opening (reviewed in
Tsujimoto and Shimizu, 2007).
The proposed PTP complex components include VDAC1 at
the OMM, ANT in the inner mitochondrial membrane (IMM),
and cyclophilin D (CypD) in the matrix (Bernardi, 1999; Green
and Evan, 2002; Shoshan-Barmatz and Gincel, 2003; Tsujimoto
and Shimizu, 2007). Recent studies on the PTP, however, have
raised doubts about the proposed members of the complex and
the importance of PTP in triggering apoptosis (Kroemer, 1997;
Kokoszka et al., 2004; Belizario et al., 2007). Mitochondria iso-
lated from animal models by knockout of genes encoding one
or more ANT or VDAC isoforms exhibit Ca2+- and oxidative
stress-induced PTP opening, suggesting that the proposed com-
ponents of the standard model of the PTP complex needs to
be reconsidered and further characterized (Kokoszka et al., 2004;
Krauskopf et al., 2006; Baines et al., 2007; Berridge et al., 2009).
On the other hand, CypD was found to be essential for MMP
mediated by Ca2+ overload and that the CypD-dependent MMP
regulates some forms of necrotic cell death but not apoptotic death
(Belizario et al., 2007).
Although the mechanism(s) responsible for PTP opening and
its physiological function have not yet been resolved, a vari-
ety of agents were found to promote or inhibit PTP opening,
including Ca2+, inorganic phosphate, various oxidizing agents,
glutamate, nucleotides, CypD ligands, gelsolin, HK, and proteins
of the Bcl-2 family. Some of these compounds have also been
shown to interact with VDAC1 directly and modify its channel
activity (Shimizu et al., 2000c; Sugiyama et al., 2002; Tsujimoto
and Shimizu, 2002; Shoshan-Barmatz and Gincel, 2003; Gin-
cel and Shoshan-Barmatz, 2004; Shoshan-Barmatz et al., 2006).
Similarly, the ANT ligands, atractyloside and bongkrekic acid,
modulate PTP opening (Haworth and Hunter, 2000). The func-
tion of PTP in apoptosis and necrosis (Rasola and Bernardi,
2011) and as a potential therapeutic target for cancer, ischemia-
reperfusion injury, and neurodegeneration were proposed
(Peixoto et al., 2012).
Osmotic matrix swelling and OMM rupture leading to non-speciﬁc
release of inter-membrane proteins into the cytosol
This model proposes that a sudden increase in IMM permeability
to solutes of low molecular weight leads to mitochondria swelling
and rupture of the OMM, allowing the efﬂux of IMS proteins,
such as Cyto c, to the cytosol (Feldmann et al., 2000). It has been
suggested that matrix swelling and OMM rupture result from a
defect in mitochondrial ATP/ADP exchange due to VDAC1 clo-
sure, as a result, for example, of removal of a normal growth factor
or exposure to G3139 (Model B, Figure 4; Vander Heiden et al.,
2000, 2001; Lemasters andHolmuhamedov, 2006). Several studies,
however, demonstrated that Cyto c release preceded membrane
potential (Δψm) loss in cerebellar granule neurons undergo-
ing apoptotic death and was not accompanied by mitochondrial
swelling or OMM rupture (Al-Abdulla et al., 1998; Desagher et al.,
1999; Wigdal et al., 2002).
Bax oligomers constitute the OMM cytochrome c-conducting
channel
A third proposed mechanism for Cyto c release suggests that
oligomeric Bax forms the Cyto c-conducting channel in the OMM
(Model C,Figure 4; Antonsson et al., 2000, 2001; Eskes et al., 2000;
Zamzami et al., 2000; Kuwana et al., 2002; Reed, 2006). Upon
apoptosis induction with STS or UV irradiation, Bax became
associated with mitochondria as a large oligomer/complex of 96–
260 kDa.While tBid enhances oligomerization of Bax (Lovell et al.,
2008), Bcl-2 prevented Bax oligomerization and insertion into the
mitochondrial membrane. Several studies, however, showed that
apoptosis can be induced in the absence of Bax (Lindenboim et al.,
2005; Mizuta et al., 2007; Wan et al., 2008), suggesting that the
protein is not obligatory for apoptosis induction and that other
mechanisms exist.
Bax and Bak oligomers form pores for pro-apoptotic factor efﬂux
during apoptosis
The appearance of a channel formed by Bax and Bak hetero-
oligomers upon apoptotic insult enabling efﬂux of pro-apoptotic
effectors has been suggested (Model D,Figure 4; Gross et al., 1998;
Desagher et al., 1999; Wei et al., 2000, 2001; Antignani and Youle,
2006). tBid was proposed to activate the generation of Bax and
Bak complexes up to 500 kDa (Sundararajan et al., 2001). At the
same time, anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, were
shown toprotect cells fromapoptosis via a blockageof theBax–Bak
interaction, subsequently preventing Cyto c release (Mikhailov
et al., 2003; Dlugosz et al., 2006).
Mitochondrial apoptosis-induced channel as a pathway for
cytochrome c release
Mitochondrial apoptosis-induced channel (MAC), a supra-
molecular high-conductance channel in the OMM, is thought to
assemble during early apoptosis and serve as the Cyto c release
channel that is regulated by Bcl-2 family members (Guo et al.,
2004; Martinez-Caballero et al., 2004, 2005; Dejean et al., 2005,
2006a,b; Model E, Figure 4). The complete molecular identity
of MAC is unknown. Recently, it was proposed that Bax is an
essential constituent of MAC in some systems, as the electrophys-
iological characteristics of MAC are very similar to those of Bax
channels, while depletion of Bax signiﬁcantly diminishes MAC
activity (Martinez-Caballero et al., 2009).
Hetero-oligomers composed of VDAC1 and Bax form the apoptotic
protein release channel
The formation of hetero-oligomers composed of VDAC1 and
Bax were also proposed as a mechanism for Cyto c efﬂux
(Model F, Figure 4; Shimizu et al., 1999; Shimizu and Tsu-
jimoto, 2000; Banerjee and Ghosh, 2004). It was found that
recombinant Bax induced permeability in liposomes containing
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VDAC, implying that VDAC can induce membrane permeabil-
ity in the presence of Bax (Shimizu and Tsujimoto, 2000). In
addition, intracellular microinjection of anti-VDAC antibod-
ies prevented Bax-induced Cyto c release (Shimizu et al., 2001).
Electrophysiological studies of Bax and VDAC in PLB revealed
that when combined, single-channel conductance rises by fac-
tors of 4 and 10 over values attained with VDAC and Bax
channels alone, respectively (Banerjee and Ghosh, 2004). More-
over, HK-I and HK-II compete with Bax for interaction with
VDAC1 (Pastorino et al., 2002). It was also demonstrated that
siRNA-mediated down-expression of VDAC1 strongly suppressed
cisplatin-induced activation of Bax (Tajeddine et al., 2008). Finally,
another version of thismodel suggests that oligomericVDAC is the
prime Cyto c release channel and that its pore is regulated by Bax
(Debatin et al., 2002).
Ceramides and the release of cytochrome c
A self-assembled ceramide-based lipid channel that forms in the
OMM was suggested as being the Cyto c release pathway (Model
G, Figure 4; Siskind et al., 2006; Stiban et al., 2008). Ceramides
were postulated to form a pore in the OMM with a diameter large
enough to accommodate Cyto c (Siskind and Colombini, 2000;
Siskind et al., 2006; Stiban et al., 2008). An alternative mechanism
proposes that ceramides promote the dissociation of Cyto c by
altering IMM lipid microdomains (Yuan et al., 2003). Another
proposal suggest that ceramides and cholesterol both affect mem-
brane microenvironments so as to favor Bax activation (Birbes
et al., 2005; Oh et al., 2006), with translocation to mitochondria
fostering propagation of the apoptotic cascade (Martinez-Abundis
et al., 2009).
VDAC1 oligomerization and release of cytochrome c
In a model describing Cyto c release developed in our group, it
is proposed that mitochondrial pore formation during apoptosis
involves the assembly of homo-oligomers of VDAC1 (Model H,
Figure 4; Zalk et al., 2005; Shoshan-Barmatz et al., 2006, 2008a;
Abu-Hamad et al., 2009). This model is based on a VDAC1 diam-
eter pore (2.5–3.0 nm; Bayrhuber et al., 2008) being large enough
for themovement of nucleotides and smallmolecules but too small
to allow passage of a folded protein, like Cyto c. Thus, a model in
which Cyto c release takes place through the formation of large
protein-conducting channel within a VDAC1 homo-oligomer or
in a hetero-oligomer containing VDAC1 and pro-apoptotic pro-
teins formed by oligomerization of VDAC1 is offered (Zalk et al.,
2005; Shoshan-Barmatz et al., 2006, 2008a; Abu-Hamad et al.,
2009). Substantial evidence for the formation of higher ordered
VDAC1-containing complexes exists (seeVDAC1Oligomerization
and Function).
Recently, it has been demonstrated that VDAC1 undergoes
oligomerization in response to apoptotic stimuli, with VDAC1
oligomerization being enhanced up to 20-fold, as revealed by
chemical cross-linking, or directly monitored in living cells using
bioluminescence resonance energy transfer (BRET; Shoshan-
Barmatz et al., 2008a; Keinan et al., 2010). Enhancement of VDAC
oligomerization was obtained regardless of the cell type or apop-
tosis inducer used, including STS, curcumin, As2O3, etoposide,
cisplatin, selenite, TNF-α, H2O2, or UV, all affecting mitochondria
FIGURE 5 | Apoptosis induction andVDAC1 oligomerization. VDAC1
oligomerization as induced by apoptosis inducers and revealed by
EGS-based cross-linking. HeLa cells were incubated for 16 h with STS
(0.2 μM) or selenite (8 μM), as described previously (Keinan et al., 2010),
washed with PBS and incubated with EGS (300 μM) at 30◦C for 10 min,
followed by SDS-PAGE (10% acrylamide) and Western blotting using
anti-VDAC1 antibodies. VDAC1 monomers, dimers, trimers, tetramers,
and multimers are indicated. The arrow indicates an anti-VDAC1
antibody-labeled protein band migrating below the position of monomeric
VDAC1. The positions of molecular weight protein standards are also
provided.
yet acting through different mechanisms (Keinan et al., 2010;
Figure 5). Conversely, the apoptosis inhibitor, DIDS, prevented
STS-induced VDAC1 oligomerization and apoptosis (Shoshan-
Barmatz et al., 2008a; Keinan et al., 2010). Moreover, VDAC1
over-expression resulted in VDAC1 oligomerization and apop-
tosis in the absence of any apoptosis stimuli (Shoshan-Barmatz
et al., 2008a). Furthermore, it was demonstrated that in cells
expressing a VDAC1 dimeric fusion protein comprising wild type
and the RuR-insensitive E72Q-mutated VDAC1 showed no pro-
tection against STS-induced apoptosis. This dominant-negative
VDAC1 mutant reveals oligomeric VDAC1 to be the active unit in
mitochondria-mediated apoptosis (Mader et al., 2010).
The molecular mechanisms triggeringVDAC1 oligomerization
upon apoptosis induction remain unknown. Post-translational
modiﬁcation of VDAC1, such as phosphorylation (Kerner et al.,
2012) or oxidation, may modulate its oligomeric state. The
involvement of lipids has been suggested recently (Betaneli et al.,
2012). The anionic lipid, phosphatidylglycerol (PG), was found to
signiﬁcantly enhance VDAC1 oligomerization in the membrane,
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whereasCLdisruptsVDAC1 supra-molecular assemblies. Interest-
ingly, during apoptosis, the level of PG in mitochondria increases,
whereas that of CL decreases (Betaneli et al., 2012). Another pro-
posed mechanism involves Cyto c detachment from its binding
site, namely CL at the IMM. Apoptotic signals leading to the oxi-
dation of CL and dissociation of Cyto c from the lipid (Ott et al.,
2002), together with our ﬁnding that VDAC1 oligomerization is
highly encouraged by Cyto c (Zalk et al., 2005), support a scenario
whereby unbound Cyto c promotes VDAC oligomerization, Cyto
c release and subsequent apoptosis.
Clearly, a more complete understanding of the mechanisms
underlyingVDAC1oligomer assembly and its role inCyto c release
will require additional study. Indeed, the multiple pathways and
mechanisms of Cyto c release presented here may co-exist within
a single model of cell death, depending on the cell type and
the nature of the stimulus (Gogvadze et al., 2006; Galluzzi and
Kroemer, 2007).
CANCER METABOLISM, HEXOKINASE, AND VDAC
In recent years, a substantial body of evidence has accumulated
indicating a correlation between alterations in cell metabolism
and cancer formation. Cancer cells undergo signiﬁcant metabolic
adaptation to fuel cell growth and division (Gatenby and Gillies,
2004; Hanahan andWeinberg, 2011; Koppenol et al., 2011). Malig-
nant cancer cells typically display high rates of glycolysis evenwhen
fully oxygenated and are subject to suppressed mitochondrial res-
piration, despite the fact that glycolysis is a less energy-efﬁcient
pathway, a phenomenon known as the “Warburg effect” (Gatenby
and Gillies, 2004; Hanahan and Weinberg, 2011; Koppenol et al.,
2011). TheWarburg effect likely provides the vast majority of can-
cerous tumors with a number of beneﬁts in the form of precursors
for the biosynthesis of nucleic acids, phospholipids, fatty acids,
cholesterol, and porphyrins. A second advantage of the Warburg
effect is its likely involvement in both tumor protection and inva-
sion. Tumor cells produce lactic acid via glycolysis and transport it
out of the cell, leading to increased acidity of the closed microen-
vironment, generating a low pH“coat.”This is proposed to protect
tumors against attack by the immune system while inducing neg-
ative effects on normal surrounding cells, aiding in preparing the
surrounding tissues for invasion. Additionally, the Warburg effect
also assures longer tumor survival time if oxygen becomes limit-
ing (Hanahan and Weinberg, 2011). Moreover, cancer-associated
abnormalities in glucose metabolism enhance cellular resistance
to apoptosis, with mitochondria playing a key role in this process
(Fadeel et al., 2008; Kroemer and Pouyssegur, 2008; Mayevsky,
2009; Fulda et al., 2010; Gogvadze et al., 2010). Finally, mitochon-
dria havebeen found toplaya role in cellular re-programming from
the catabolic to the anabolic modes (Fadeel et al., 2008; Kroemer
and Pouyssegur, 2008; Mayevsky, 2009; Gogvadze et al., 2010),
with such metabolic ﬂexibility and cellular hierarchy being crucial
in metastatic cancer (Berridge et al., 2010).
Such metabolic re-programming of cancer cells includes
marked over-expression of mitochondrial-bound HK isoforms,
considered as the rate-limiting enzyme of glycolysis and serving
as the biochemical gate of this pathway (Pedersen et al., 2002;
Mathupala et al., 2006; Pedersen, 2007; Shoshan-Barmatz et al.,
2010). HK interacts withVDAC1 at the OMM and forms the main
interface between mitochondria and the cytosol. VDAC1 con-
tributes to cancermetabolism via transport of variousmetabolites,
mediating ATP/ADP exchange across the OMM and is, therefore,
deﬁned as the “food channel.” HK, by association with VDAC1,
gains direct access to mitochondrial ATP, reaching VDAC1 via
the ANT in the IMM, allowing it to phosphorylate and “trap”
any incoming glucose (Pedersen, 2008). With this direct cou-
pling of mitochondrially generated ATP to incoming glucose via
VDAC1-bound HK, mitochondria regulate glycolytic ﬂux with
that of the tricarboxylic acid (TCA) cycle andATP synthase to bal-
ance the energy requirements of the tumor cell with biochemical
requirements for metabolites (i.e., the anaplerotic and cataplerotic
pathways, respectively) or metabolite precursors that are required
by the tumor (Pedersen et al., 2002; Mathupala et al., 2006; Peder-
sen, 2007; Shoshan-Barmatz et al., 2010). Thus, both the glycolytic
pathway and other seminal metabolic pathways, like the pentose
phosphate shunt, are regulated via the energy-coupling resulting
from the formation of the VDAC1-bound HK complex. As part
of a system that impacts cell growth, the VDAC1–HK complex
represents a remarkable target for cancer therapy (see The Inter-
action of VDAC1 with Hexokinase Regulates Cell Bioenergetics
and Apoptosis).
VDAC1 ASSOCIATION WITH PROTEINS AND CANCER
The localization of VDAC1 at the OMM provides structural and
functional anchoring sites for a diverse set of cytosolic proteins
that together with VDAC1 mediate metabolic and signaling cross-
talk between cytosol and mitochondria (Table 1). VDAC1 displays
binding sites for glycerol kinase (Adams et al., 1991),HK (Azoulay-
Zohar et al., 2004; Pastorino et al., 2005; Abu-Hamad et al., 2008;
Goldin et al., 2008; Shoshan-Barmatz et al., 2008b; Arzoine et al.,
2009), creatine kinase (Schlattner et al., 2001), C-Raf kinase (Le
Mellay et al., 2002), ANT (Vyssokikh and Brdiczka, 2003), the
peripheral benzodiazepine receptor [also known as translocator
protein (TSPO); Veenman et al., 2007], tubulin (Rostovtseva et al.,
2008b), the dynein light chain, mtHSP70, the ORDIC channel,
GAPDH (Shoshan-Barmatz and Israelson, 2005), actin (Xu et al.,
2001), and gelsolin (Kusano et al., 2000), as well as Bcl-2 family
members (Shoshan-Barmatz et al., 2006; Adams and Cory, 2007;
Llambi and Green, 2011). Interaction with apoptosis-regulating
proteins, such as HK and Bcl-2 family members, make VDAC1
a key protein in apoptosis regulation (Tsujimoto and Shimizu,
2002). Here, we focus on those VDAC1-interacting proteins
showing modiﬁed levels of expression in cancer cells.
THE INTERACTION OF VDAC1 WITH HEXOKINASE REGULATES CELL
BIOENERGETICS AND APOPTOSIS
HK expression and bioenergetics regulation in cancer cells
One of the signature phenotypes of highly malignant, poorly
differentiated tumors is their high rate of glycolysis, leading to
enhanced lactate generation (Brahimi-Horn et al., 2007). This
property is frequently dependent on the marked over-expression
of VDAC1-bound HK (Rose et al., 1974; Gottlob et al., 2001;
Bryson et al., 2002; Pedersen et al., 2002; see Cancer Metabolism,
Hexokinase and VDAC). HK thus lies at the apex of the glycolytic
pathway that provides the metabolic intermediates required by
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the biosynthetic pathways on which a transformed cell places such
heavy demand (Pedersen, 2007; Mathupala et al., 2010).
Hexokinase catalyzes the rate-limiting step in glycolysis, the
ATP-dependent phosphorylation of glucose to G-6-P. The mito-
chondria bound-isoforms, HK-I and HK-II, were found to be
over-expressed in many cancers, including colon, prostate, lym-
phoma, glioma, gastric adenomas, carcinomas, and breast cancers
(Gottlob et al., 2001; Bryson et al., 2002; Mathupala et al., 2010).
The elevated levels of mitochondria-bound HK in cancer cells is
thus suggested to play a pivotal role in promoting cell growth
and survival in rapidly growing, highly glycolytic tumors and
in protecting against mitochondria-mediated cell death (Mathu-
pala et al., 2006). The association/dissociation of HK with/from
VDAC1 and the switching of VDAC1 between an “open” and
a “closed” state regulate cross-talk between mitochondria and
the cytosol (Shoshan-Barmatz et al., 2006, 2010). This control is
important in maintaining the mitochondria respiration and gly-
colysis equilibrium at the heart of the energetic and metabolic
homeostasis of the cancer cell. Cancer cell, however, possess an
escape mechanism that intervenes when G-6-P accumulates and
dissociates HK from VDAC (Azoulay-Zohar et al., 2004).
VDAC1 is the mitochondrial binding site of HK
The interaction of HKwith themitochondria, and speciﬁcallywith
VDAC1, has shifted our view of HK as predominantly fulﬁlling a
metabolic role to one of regulation of apoptotic responsiveness
of the cell, making the VDAC1–HK complex a target for thera-
peutic purposes (Pastorino et al., 2002; Azoulay-Zohar et al., 2004;
Pastorino et al., 2005; Shoshan-Barmatz et al., 2006, 2008b, 2009;
Abu-Hamad et al., 2008; Goldin et al., 2008; Pastorino and Hoek,
2008; Arzoine et al., 2009).
The interaction between HK-I and VDAC1 was ﬁrst demon-
strated in a reconstituted system where HK-I decreased the
channel conductance of VDAC1, an effect that was reversed by
G-6-P, shown to detach HK from isolated mitochondria (Azoulay-
Zohar et al., 2004). The interaction between HK-I and VDAC1
was again demonstrated by co-immunoprecipitation (Shoshan-
Barmatz et al., 2008a). The co-localization of HK-I with each of
the three isoforms of VDAC1 was demonstrated using two-color
stimulated emission depletion (STED) microscopy (Neumann
et al., 2010). TheHK-I–VDAC1 interaction can be abrogated upon
mutagenesis of a singleVDAC1 residue (Glu73,Glu202, orGlu65),
resulting in an elimination of HK-mediated protection against
apoptosis and channel closure (Zaid et al., 2005; Abu-Hamad et al.,
2008). N-terminally truncatedVDAC1 is incapable of binding HK
(Abu-Hamad et al., 2009) or Bcl-xL (Arbel et al., 2012). Moreover,
when the N-terminal region α-helix structure in VDAC1 was per-
turbed, the binding of HK was reduced (Geula et al., 2012a). It
was proposed that the N-terminal region of HK-I is inserted into
the channel pore, where it interacts with the N-terminal region
of VDAC1 (Rosano, 2011). It should be noted that there is strong
residue conservation between the HK-I and HK-II N-termini, and
that such conservation is not shared by the other two non-bound
mitochondrial isoforms, HK-III and HK-IV.
The VDAC1–HK interaction was shown to be negatively regu-
lated by phosphorylation, when GSK3β is up-regulated (Pastorino
et al., 2005). Finally,VDAC1-based peptides were found to interact
with puriﬁed HK and when expressed in cells over-expressing HK,
prevented the anti-apoptotic activity of HK (Arzoine et al., 2009).
HK-linked protection against cell death is mediated
via interaction with VDAC1
In vitro and in vivo studies have shown that elevated levels
of mitochondria-bound HK in cancer cells also protect against
mitochondria-mediated apoptosis via direct interaction with
VDAC1.
Mitochondrially associatedHKhas been shown toprotectHeLa
and HEK cells from entering apoptosis (Bryson et al., 2002). This
protection was related to a blockade of the interaction of the
pro-apoptotic protein, Bax, with VDAC1 (Bryson et al., 2002).
Moreover, over-expression of HK-I or HK-II in tumor-derived
cell lines suppressed STS-induced Cyto c release and apopto-
sis (Azoulay-Zohar et al., 2004; Zaid et al., 2005; Arzoine et al.,
2009). A decrease in apoptosis and an increase in cell prolifera-
tion have also been reported to be induced by HK-II expression in
the NIH-3T3 (Fanciulli et al., 1994) and rat 1a cell lines (Gottlob
et al., 2001). Importantly, mutagenesis studies revealed that single
mutations or N-terminal truncation in VDAC1 prevented HK-
I-mediated protection against apoptosis and channel closure in
a reconstituted membrane system (Zaid et al., 2005; Abu-Hamad
et al., 2008, 2009; Shoshan-Barmatz et al., 2009). In addition, bind-
ing of HK-II to mitochondria inhibits Bax-induced Cyto c release
and apoptosis (Pastorino et al., 2002). HK binding to VDAC1 is
regulated by protein kinases, notably GSK-3β (Pastorino et al.,
2005) and protein kinase C (PKC; Pastorino and Hoek, 2008), as
well as by the cholesterol content of the OMM (Pastorino and
Hoek, 2008).
HK interaction with VDAC1, advantages to cancer cells
Several mechanisms by which HK binding to VDAC1 protects
against apoptosis and promotes cell survival can be considered.
These include controlling energy and metabolic homeostasis, as
well as preventing VDAC1-mediated Cyto c release and shield-
ing VDAC1 from pro-apoptotic factor binding, thus offering the
tumor cell protection from cell death in a synergic manner. The
advantages to cancer cells of HK binding to VDAC1 include:
Energy and metabolite production and access. Hexokinase
bound toVDAC1 provides cells with metabolic advantages, allow-
ing enhanced cell growth (Pedersen, 2007). Anchoring of HK to
VDAC1 offers the enzyme direct access to mitochondrial sources
of ATP and greater afﬁnity for Mg2+-ATP (Bustamante and Ped-
ersen, 1980; Pedersen, 2008). HK bound to the cytosolic face of
VDAC1 acts as a gate, regulating the trafﬁc of various metabo-
lites through theVDAC1 (Azoulay-Zohar et al., 2004). In addition,
VDAC1-bound HK is less sensitive to inhibition by its product,
G-6-P (Azoulay-Zohar et al., 2004), thus avoiding product inhibi-
tion. TheHK–VDAC1 interaction increases energy andmetabolite
production of the high energy-demanding cancer cells, allow-
ing for maintenance of a high glycolytic ﬂux rate in tumors
(Azoulay-Zohar et al., 2004).
VDAC1-bound HK acts as an anti-apoptotic protein. Accumu-
lated evidence demonstrated that HK-I and HK-II also function
as anti-apoptotic proteins when bound to VDAC1, while their
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detachment enabled activation of apoptosis (Pastorino et al., 2002,
2005; Azoulay-Zohar et al., 2004; Shoshan-Barmatz et al., 2006,
2008b, 2009; Abu-Hamad et al., 2008; Goldin et al., 2008; Pas-
torino and Hoek, 2008; Arzoine et al., 2009). Disruption of HK
binding to VDAC1 by mutation in VDAC1 or by addition of
VDAC1-based peptides decreased the survival of cancer cells
(Arzoine et al., 2009).
Hexokinase interactionwithVDAC1protects against activation
of apoptosis by Bax or Bak (Pastorino et al., 2002; Majewski et al.,
2004b; Pastorino andHoek, 2008). The detachment of HK-II from
the mitochondria was found to markedly potentiate the onset of
caspase-2-induced mitochondrial damage (Shulga et al., 2009).
Regulation of ROS production by HK. Reactive oxygen species
act as second messengers in cell signaling and are essential for
multiple biological processes in normal cells. However, ROS can
also provoke damage to multiple cellular organelles and processes
(Auten and Davis, 2009). ROS production is usually increased in
cancer cells due to oncogene activation (Zhang et al., 2011; see
VDAC1 Function in ROS Release, ROS-mediated Apoptosis and
Interaction with NO). Mitochondria-associated HK was shown to
reduce mitochondrial ROS generation (da-Silva et al., 2004), with
HK-I and HK-II reducing intracellular levels of ROS (Sun et al.,
2008). Moreover, expression of both HK-I and HK-II was found
to protect against oxidant-induced cell death (Ahmad et al., 2002;
Bryson et al., 2002). Thus, detachment of HK from VDAC1 could
lead to increased ROS generation and release to the cytoplasm,
thereby activating cell death.
Stabilization of both HK and VDAC1. VDAC1, containing an
odd number of β-strands, presents conformational intrinsic insta-
bility within the ﬁrst four β-strands (β1–4), relative to other
VDAC1 regions (Bayrhuber et al., 2008).
In silico studies of theVDAC1–HK-I interaction predicates that
both proteins attain a more stable state through protein–protein
interaction (Rosano, 2011). It is proposed that upon binding with
the N-terminal helix of HK-I,VDAC1 acquires higher stability via
the formation of a network of chemical bonds both due to direct
protein–protein contacts and to hydrogen bonds mediated by an
ATP molecule and an Mg2+ ion (Rosano, 2011).
Increased synthesis and uptake of cholesterol. Cancer cells have
been shown to exhibit a 2- to 10-fold increase in mitochon-
drial cholesterol content, in comparison to liver mitochondria
(Baggetto et al., 1992). It has been proposed that the increased
binding of HK to the mitochondria of cancer cells may play a role
in mediating increased synthesis and uptake of cholesterol into the
mitochondria of cancer cells (Pastorino and Hoek, 2008).
Disruption of the HK–VDAC interaction as an approach
to cancer therapy
If one considers the metabolic importance of both VDAC1 and
HK, the role that HK fulﬁlls in promoting tumor cell survival
and the function of the HK–VDAC1 interaction in regulating
apoptosis, as well as other functions as presented above, then
disruption of the HK–VDAC1 complex represents an attractive
target for cancer therapy and may form the basis for novel anti-
cancer drugs. Indeed, several different compounds have been
employed to disrupt the HK–VDAC1 association, resulting in
apoptotic cell death. These include peptides corresponding to
the amino terminus of both HK-I (Gelb et al., 1992) and HK-
II (Pastorino et al., 2002), clotrimazole (Penso and Beitner, 1998;
Pastorino et al., 2002; Shoshan-Barmatz et al., 2008b) and a cell-
permeable HK-II-based peptide (Majewski et al., 2004a). Methyl
jasmonate (a plant-derived stress hormone) binds to and detaches
mitochondria-bound HK from several cancer cell types (Goldin
et al., 2008). HK detachment can be visualized using HK–GFP.
Cell expression of HK-I–GFP showedpunctuated distribution that
co-localized with MitoTracker Red (Figure 6), suggesting a mito-
chondrial localization. The induction of apoptosis by STS resulted
in HK–I-GFP detachment, as reﬂected by the diffuse ﬂuorescence
seen (Figure 6).
The small molecule alkylating agent, 3-bromopyruvic acid
(3BP) was found to be phosphorylated by HK and to inhibit
glycolytic rate in VX2 tumors (Ko et al., 2001). 3BP covalently
modiﬁes protein cysteine residues, resulting in rapid activity loss
(Meloche and Monti, 1975; Ko and McFadden, 1990; Pereira
da Silva et al., 2009). In animal models, 3BP showed high efﬁ-
cacy against advanced stage malignant tumors by inhibiting both
glycolysis and mitochondrial energy generation, possibly by inter-
fering with the HK–VDAC1 complex (Berridge et al., 2010). Thus,
3BP is proposed to target metabolism and blocks energy sup-
plies. Other studies demonstrated the potential of 3BP as a potent
anti-cancer agent in humans (Ko et al., 2012). Current knowledge
related to 3BP and its promise as a future cancer therapeutic are
the focus of a special 2012 issue of the Journal of Bioenergetics
and Biomembranes (JOBB 44-1, 2012).
In conclusion, since VDAC1-bound HK is essential for tumor
cells, conferring several advantages (see HK-linked Protection
Against Cell Death is Mediated via Interaction with VDAC1),
including protection against apoptotic events and promoting
aerobic glycolysis, the detachment of HK from VDAC1 offers
a novel therapeutic strategy to augment apoptosis, revert the
hyper-glycolytic state and enhance the therapeutic efﬁcacy of
conventional chemotherapeutic agents.
MEMBERS OF THE Bcl-2 FAMILY OF PROTEINS INTERACT WITH VDAC
The B cell lymphoma/leukemia-2 (Bcl-2) family of proteins plays
an essential role in the control of apoptosis (Brown, 1997) at
the interface with mitochondria. The Bcl-2 family consists of
more than 20 pro-apoptotic (e.g., Bid, Bax, and Bak) and anti-
apoptotic (e.g., Bcl-2 and Bcl-xL) members, all characterized by
the presence of Bcl2 homology (BH) domains (Adams and Cory,
2007; Youle and Strasser, 2008). Accordingly, these proteins can
be sub-divided into three main groups, based on the regions
of the BH domain they contain and their function, namely the
multi-domain anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and
Bﬂ-1/A1), the multi-domain pro-apoptotic [Bcl-2-associated X
protein (Bax) and Bak], and the BH3-only pro-apoptotic (Bid,
Bim, Bad, Bik, Noxa, PUMA, Bmf, and Hrk) proteins (Certo
et al., 2006). The anti-apoptotic members of the Bcl-2-family
contribute to tumor initiation, disease progression, and drug resis-
tance (Miyashita and Reed, 1993; Adams and Cory, 2007). Indeed,
enhanced expression of anti-apoptotic Bcl-2 family members was
shown to be associated with the resistance of many tumors to
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FIGURE 6 | Detachment of mitochondrial-bound HK-I-GFP induced by
STS.To demonstrate HK-I binding to mitochondria (i.e., VDAC) as well as
detachment, a HK-I–GFP fusion protein was expressed in HEK–T cells.
Confocal ﬂuorescence microscopy showed that in control cells expressing
HK-I–GFP, the ﬂuorescence is punctuated, as expected for mitochondrial
distribution. On the other hand, induction of apoptosis by STS detaches
mitochondrial-bound HK-I–GFP. HEK–T cells were transfected to express
HK-I–GFP and after 48 h were exposed to STS (0.8 μM), stained with 25 nM
of the mitochondrial marker MitoTracker Red and visualized with confocal
microscopy. The punctuated HK-I–GFP ﬂuorescence, originally co-localized
with mitochondria (control), as also reﬂected in the co-localization with
MitoTracker Red (Merge panel), was converted to diffuse labeling of the
cytosol after exposure to STS. Images are representative microscopic ﬁelds
from one of three similar experiments (scale bar = 5 μm).
chemotherapy (Sentman et al., 1991; Adams and Cory, 2007). For
example, in multiple studies, increased levels of Bcl-2, Bcl-xL, and
Mcl-1 proteins were linked to survival of multiple myeloma cells
and resistance to chemotherapy (Oancea et al., 2004), while in
most cases of chronic lymphocytic leukemia (CLL), elevated Bcl-2
mRNA and protein levels are noted (Tsujimoto et al., 1984).
The mechanism whereby Bcl2 family members control apop-
tosis is still not fully understood. However, it is well established
that their activities involve controlling OMM permeability (Scor-
rano et al., 2003; Adams and Cory, 2007; Youle and Strasser,
2008). Accumulated ﬁndings linked the activity of both anti-
apoptotic and pro-apoptotic proteins to their association with
VDAC (Shimizu and Tsujimoto, 2000; Shimizu et al., 2000b;
Sugiyama et al., 2002; Shi et al., 2003a; Tsujimoto, 2003; Malia
and Wagner, 2007; Tajeddine et al., 2008; Arbel and Shoshan-
Barmatz, 2010). VDAC1 interacts with Bax, Bim, Bcl2, and Bcl-xL
in isolated mitochondria and in reconstituted membrane sys-
tems (Shimizu et al., 2000b; Rostovtseva et al., 2004; Malia and
Wagner, 2007; Arbel et al., 2012). Puriﬁed C-terminally trun-
cated Bcl2 and Bcl-xL interact with VDAC1 and reduced the
channel conductance of wild type but not of certain mutated
forms of VDAC1 (Arbel and Shoshan-Barmatz, 2010; Arbel et al.,
2012) or N-terminally truncated VDAC (Abu-Hamad et al., 2009;
Arbel et al., 2012). Similarly, both Bcl2 and Bcl-xL prevented
apoptosis as induced by various stimuli in cells expressing wild
type but not mutated VDAC1 (Abu-Hamad et al., 2009; Arbel
and Shoshan-Barmatz, 2010; Arbel et al., 2012). It was proposed
that VDAC1 interacts with both Bax and Bcl-xL to form a ter-
tiary complex (Shi et al., 2003a). A direct interaction between
Bcl-xL and VDAC1 was demonstrated by NMR (Malia and Wag-
ner, 2007). Interaction of the putative loop region of VDAC1
with Bcl-xL was proposed (Shi et al., 2003a). Bcl-xL was also
shown to affect VDAC oligomerization, as revealed by chemical
cross-linking of micelle-bound VDAC, shifting the equilibrium
of VDAC from the trimeric to the dimeric state (Malia and
Wagner, 2007). Furthermore, synthetic peptides correspond-
ing to the VDAC1 N-terminal region and other cytosol-facing
VDAC1 sequences bound Bcl2 and Bcl-xL (Shi et al., 2003a; Abu-
Hamad et al., 2009; Shoshan-Barmatz et al., 2009; Arbel and
Shoshan-Barmatz, 2010; Arbel et al., 2012). Such peptides, in cell-
penetrating form or expressed in the cell, were able to suppress
the anti-apoptotic activities of Bcl2 and Bcl-xL in cells (Abu-
Hamad et al., 2009; Arbel and Shoshan-Barmatz, 2010; Arbel
et al., 2012). Thus, VDAC1-based peptides, targeting the anti-
apoptotic activity of Bcl-xL and Bcl2, can serve as potential cancer
therapeutics.
Bax and VDAC reconstituted into liposomes were shown to
form a new channel, with a conductance 4–10 times larger than
that of the individual proteins (Shimizu et al., 2000b), and with
such increase being prevented by Bcl-xL. The interaction of Bax
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and Bim with VDAC leads to Cyto c release, with Bcl-xL and anti-
VDAC antibodies preventing this release (Shimizu et al., 2001).
It has also been shown that Bid but not Bax modulates VDAC
channel conductance (Rostovtseva et al., 2004).
In VDAC1-depleted cells, cisplatin-induced activation of Bax
was inhibited (Tajeddine et al., 2008), suggesting that VDAC1
is involved in Bax-mediated apoptosis. Furthermore, Bcl-2 and
Bcl-xL blocked As2O3-induced VDAC dimerization (Zheng et al.,
2004). These results indicate that Bcl-2 family proteins regulate
VDAC-mediated apoptosis and hence, the release of apoptogenic
proteins from mitochondria.
VDAC AND THE TRANSLOCATOR PROTEIN
Translocator protein is an 18-kDa integral membrane protein,
originally identiﬁed as the peripheral benzodiazepine receptor or
isoquinoline-binding protein (Korkhov et al., 2010), that is over-
expressed in breast, prostate, colon, and brain cancer, with protein
expression linked to cancer progression and poor survival rates
(Batarseh and Papadopoulos, 2010). LikeVDAC1, TSPO is located
in the OMM and was proposed to activate PTP opening, leading
to apoptosis (Levin et al., 2005; Veenman et al., 2007; Sileikyte
et al., 2011). Interactions between TSPO and VDAC are thought
to play a role in apoptosis (Gavish et al., 1999; Levin et al., 2005;
Veenman et al., 2007). High-afﬁnity ligand occupancy of TSPO
was shown to attenuate anti-neoplastic agent-induced apoptosis
(Kugler et al., 2008). The observations that TSPO is involved in
the generation of ROS and that TSPO association withVDAC may
enhance ROS production prior to apoptotic induction, indirectly
links bothproteins (Golani et al., 2001;Veenmanet al., 2002,2007).
Still, there is no direct evidence for a TSPO–VDAC1 interaction at
the molecular level.
INTERACTION OF VDAC1 WITH AND REGULATION
BY CYTOSKELETAL PROTEINS
In cancer, morphogenic changes are required for high prolifera-
tive rates, the acquisition of inappropriate migratory patterns, and
invasive characteristics (Hall, 2009). Alterations in the dynamics
of the actin and tubulin components of the cytoskeleton are well-
known consequences of signaling and the triggering of responses
like apoptosis (Franklin-Tong and Gourlay, 2008; Rostovtseva
and Bezrukov, 2012). Mitochondria are dynamic organelles that
actively travel along the cytoskeleton within the cell. Within this
framework, speciﬁc association ofVDAC1with tubulinwas shown
by co-immunoprecipitation (Carre et al., 2002) and by tubulin-
induced VDAC1 closure (Rostovtseva et al., 2008a). A model was
proposed whereby the negatively charged C-terminus of tubu-
lin penetrates into the positively charged VDAC1 pore, leading
to decreased channel conductance (Rostovtseva et al., 2008b). It
was proposed that tubulin, VDAC1 and mitochondrial creatine
kinase (MtCK) are members of a super complex that is struc-
turally and functionally coupled to the ATP synthasome (Saks
et al., 2010). Recent evidence indicates that the lipid composi-
tion of the membrane is capable of controlling tubulin–VDAC
interactions, thus tuning VDAC sensitivity to blockage by tubu-
lin (Rostovtseva et al., 2012). Similarly, it has been reported that
tubulin–VDAC interactions can be regulated by varying the mem-
brane surface charge (Gurnev et al., 2012). In a cellular model
of cardiomyocyte physiology, the super complex presents a dif-
ferent composition, namely one in which tubulin is replaced
by HK and MtCK is absent, infusing mitochondrially gener-
ated ATP into the glycolytic pathway and thereby contributing
to the Warburg effect (Saks et al., 2010). Other proteins associ-
ated with cytoskeleton dynamics, such as gelsolin (Kusano et al.,
2000), adseverin or scinderin (SCIN;Miura et al., 2012), have been
reported to associatewithVDAC,with concomitant anti-apoptotic
effects.
All of these VDAC1–protein interactions establish a new
interplay between kinase signaling pathways, mitochondrial res-
piration, and the highly dynamic microtubule network char-
acteristic of cancerogenesis and cell proliferation. VDAC1, as
the common denominator in all the interactions described
above, thus presents a single unique target for efforts address-
ing cell physiological, metabolic, and morphological aspects of
cancer.
INTERACTION OF VDAC1 WITH VIRAL PROTEINS
Many viruses encode for proteins acting on mitochondria, in gen-
eral, on VDAC1, in particular, or directly targeting proteins in the
apoptotic pathway (Boya et al., 2001, 2003; Everett and McFad-
den, 2001; Irusta et al., 2003; Verrier et al., 2003). Other viruses
inﬂuence apoptosis by mimicking Bcl-2 family proteins, chang-
ing their expression levels or directly interacting with Bcl-2 family
proteins (Halestrap et al., 2002; Boya et al., 2004). HIV-1 offers
an excellent example of neuronal and immunological-destructive
apoptosis involving mitochondria (Sui et al., 2004; Perfettini et al.,
2005). HIV-1 envelope proteins can triggermitochondrial apopto-
sis, increasing cytosolic Ca2+, ROS, and transcriptional activation
of p53, thus increasing the expression of pro-apoptotic pro-
teins, such as Bax (Castedo et al., 2003). The PB1-F2 protein of
the inﬂuenza A virus, when localized in mitochondria, induces
alteration of mitochondrial morphology, dissipation of the mito-
chondrial membrane potential, and cell death and has been
reported to interact directly with VDAC (Zamarin et al., 2005;
Danishuddin et al., 2009). Hepatitis B virus (HBV) is another
mitochondria-interacting virus (Boya et al., 2003, 2004; Shirakata
and Koike, 2003). The HBx protein is highly homologous to
VDAC1 and is proposed to “poison” the homo-oligomeric state
of VDAC1, creating hetero-oligomeric structures that induce per-
meability of the mitochondria, allowing Cyto c release (Stanley
et al., 1995; Rahmani et al., 2000; Shoshan-Barmatz et al., 2006;
Goncalves et al., 2007; Hoogenboom et al., 2007). This action of
HBx can result in the development of hepatocellular carcino-
mas (Rahmani et al., 2000). In infected liver cell lines, hepatic
virus (HEV) not only induced up-regulation of VDAC expres-
sion in infected human hepatoma cell lines but also encouraged
higher levels of VDAC oligomerization, leading to apoptosis
(Moin et al., 2007).
VDAC1 EXPRESSION LEVELS IN HEALTHY
AND CANCER CELLS
In higher eukaryotes, VDAC1 is the most predominant isoform
expressed. Several studies have shown that alterations in VDAC1
expression affect both the ability of cells to generate energy and
their sensitivity to apoptosis-inducing reagents.
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VDAC EXPRESSION LEVELS IN CANCERS AND ENHANCEMENT BY
PRO-APOPTOTIC DRUGS
Several studies have demonstrated remarkable differences in the
expression levels of VDACs between tumor cells and normal tis-
sues. VDAC1 expression in several cancer cell lines was higher
than in the control ﬁbroblast cell line (Simamura et al., 2006,
2008). NSCLC cells speciﬁcally exhibited high expression levels
of VDAC1. This was shown to directly correlate with poor out-
come in early stage NSCLC, thus establishing an association with
aggressive tumor behavior (Grills et al., 2011). In addition, in sev-
eralmelanoma and prostate cancer cell lines, a correlation between
levels of VDAC1 expression and induction of Cyto c release by
G3139 was demonstrated (Lai et al., 2006). In a proteomic analysis
of aging-related proteins in human normal colon epithelial tis-
sues, signiﬁcant up-regulation of 19 proteins was noted, including
VDAC1 and VDAC2 (Li et al., 2007).
Several cancer treatments were found to enhance expression
of VDAC. Up-regulation of VDAC1 expression was observed in
three different acute lymphoblastic leukemia (ALL) cell lines (697,
Sup-B15, andRS4;11) followingprednisolone treatment, anobser-
vation that can be explored for predicting eventual outcome
in childhood ALL (Jiang et al., 2011). VDAC1 over-expression
was observed in a cisplatin-sensitive cervix squamous cell car-
cinoma cell line (A431) when exposed to cisplatin, while in
a cisplatin-resistant cell line (A431/Pt), the treatment resulted
in down-regulation of VDAC1 (Castagna et al., 2004). Up-
regulation of VDAC has been reported upon UV irradiation of
apoptosis-sensitive cells (Voehringer et al., 2000). When A375
human malignant melanoma cells were treated with the tyrosi-
nase inhibitor, arbutin, a potential anti-tumor agent (Nawarak
et al., 2009),VDAC1 expression level was found to be up-regulated
(Cheng et al., 2007). In addition, ROS was found to induce up-
regulation of VDAC that could be prevented by the ROS chelator,
epigallocatechin (Jung et al., 2007).
The relationship between VDAC1 expression levels and sensi-
tivity to various treatments was presented in several studies. The
PC3 and DU145 prostate cancer cell lines are relatively resistance
to apoptosis as induced by G3139 and were found to express less
VDAC than did G3139-sensitive LNCaP cells (Lai et al., 2006).
Similarly, reducing VDAC1 expression by siRNA efﬁciently pre-
vented cisplatin-induced apoptosis and Bax activation in NSCLC
(Tajeddine et al., 2008), attenuated endostatin-induced apoptosis
(Yuan et al., 2008) and inhibited selenite-induced PTP opening
(Tomasello et al., 2009). The anti-cancer activity of furanonaph-
thoquinones (FNQs) was increased uponVDAC1 over-expression
and decreased upon silencing of VDAC1 expression by siRNA
(Simamura et al., 2008).
Finally, it has also been shown that the CD45 expression is
accompanied by elevatedVDAC1 expression in myeloma cells sen-
sitized to a diverse set of apoptotic stimuli via the mitochondrial
pathways (Liu et al., 2006).
SILENCING OF VDAC1 EXPRESSION
Among the complex array of genetic changes accompanying cancer
development, all cancerous cells develop altered metabolism, with
VDAC1 and HK playing important functions in this metabolic
reprograming (see The Interaction of VDAC1 with Hexokinase
Regulates Cell Bioenergetics and Apoptosis). VDAC1 contributes
to cancer metabolism via transport of various metabolites, medi-
ating ATP/ADP exchange across the OMM and by the binding
and channeling of mitochondrial ATP directly to HK (see Cancer
Metabolism, Hexokinase and VDAC). The importance of VDAC1
for cancer cells is further reﬂected in the ﬁndings that silencing
VDAC1 expression reduced cellular ATP levels and cell growth
(Abu-Hamad et al., 2006). Furthermore, when HeLa cervical can-
cer cells stably expressing shRNA directed against hVDAC1 were
injected into nude mice, the development of a solid tumor was
inhibited (Koren et al., 2010). It has also been shown that VDAC1
silencing potentiates H2O2-induced apoptosis and impairs mito-
chondrial Ca2+ loading, while silencing VDAC2 had the opposite
effects (De Stefani et al., 2012). Together, these ﬁndings indicate
that over-expression of VDAC1 in cancer cells could contribute to
the high glycolytic phenotype seen.
ENHANCEMENT OF VDAC1 EXPRESSION, OLIGOMERIZATION AND
APOPTOSIS INDUCTION
As presented above (see VDAC Expression Levels in Cancers and
Enhancement by Pro-apoptotic Drugs), the expression level of
VDAC1 serves as a crucial factor in the process of mitochondria-
mediated apoptosis as induced by various means. Indeed, over-
expression of VDAC from different sources, such as yeast, rice,
ﬁsh, mice, and humans, was found to induce apoptosis (Godbole
et al., 2003; Zaid et al., 2005; Ghosh et al., 2007; Lü et al., 2007).
Over-expression of murine (m)VDAC1or rat (r)VDAC1 inU-937
cells resulted in apoptotic cell death (Zaid et al., 2005). Moreover,
over-expression of rice VDAC induced apoptosis (Godbole et al.,
2003) that was blocked by Bcl-2 and the VDAC channel inhibitor,
DIDS. Similar results were obtained following transfection of
ﬁsh cells to express Paralichthys olivaceus VDAC (Lü et al., 2007).
Over-expression of VDAC1 causes depolarization of the IMM and
activation of the PTP (De Pinto et al., 2007; Tomasello et al., 2009).
The mechanism underlying cell death induced by VDAC1
over-expression is not fully understood. However, recent stud-
ies demonstrated that VDAC1 over-expression is accompanying
by its oligomerization (Zalk et al., 2005; Goncalves et al., 2007;
Hoogenboom et al., 2007; Malia and Wagner, 2007; Shoshan-
Barmatz et al., 2008a,b; Zeth et al., 2008; Keinan et al., 2010).
VDAC1 has been shown to form different oligomeric states,
namely monomers, dimers, trimers, tetramers, hexamers, and
higher-order oligomers (see VDAC1 Oligomerization and Func-
tion). Moreover, the supra-molecular assembly of VDAC1 in
cultured cells is highly enhanced upon apoptosis induction, sup-
porting the involvement of VDAC1 oligomerization in Cyto c
release and thus, in apoptosis (Shoshan-Barmatz et al., 2008b;
Keinan et al., 2010). Moreover, VDAC1 over-expression resulted
in its oligomerization in the absence of any apoptosis stimuli
(Shoshan-Barmatz et al., 2008b). It should be noted that apoptosis
induced by VDAC1 over-expression shares common features with
apoptosis induced by other stimuli (e.g., STS,H2O2), as is the case
for inhibition by RuR, Bcl2, HK-I over-expression, or DIDS, all
agents that interact with VDAC1 (Shoshan-Barmatz et al., 2006).
Finally, HEV-infected human hepatoma cells showed enhanced
VDACexpression, leading toVDAColigomerization and apoptosis
(Moin et al., 2007).
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Thus, the over-expression of VDAC1, as induced by drugs, such
as arbutin, prednisolone, or cisplatin, or by viral proteins or UV
irradiation, as well as the correlation between drug effectiveness
and VDAC expression, suggest that the anti-cancer activities of
these drugs is associated with VDAC levels. This is further sup-
ported by the ﬁnding that cisplatin-induced apoptosis is inhibited
in cells silenced for VDAC1 expression (De Pinto et al., 2007;
Tomasello et al., 2009). In addition, endostatin-induced apoptosis
was decreased upon silencing VDAC1 expression, and enhanced
by over-expression of VDAC1 (Yuan et al., 2008). We thus pro-
pose that the high levels of VDAC1 promote its oligomerization,
leading to apoptosis (Shoshan-Barmatz et al., 2008b; Keinan
et al., 2010). Accordingly, anti-cancer strategies that speciﬁcally
up-regulate VDAC1 levels in cancer cells may activate the mito-
chondrial apoptotic pathway, with concomitant beneﬁt to the
patient.
VDAC1 FUNCTION IN ROS RELEASE, ROS-MEDIATED
APOPTOSIS AND INTERACTION WITH NO
MITOCHONDRIA, ROS, AND OXIDATIVE STRESS
Reactive oxygen species serve important roles in diverse events,
such as cellular proliferation, differentiation, and migration. It is
now accepted that cellular “redox” signaling is involved in regulat-
ing normal processes and disease progression, including angio-
genesis, oxidative stress, aging, and cancer. Cellular levels of
ROS are linked to anti-tumor immunity, the oxidative tumor
microenvironment, proliferation, and death of cancer cells
(Manda et al., 2009).
Cancer cells exhibit high basal levels of oxidative stress due
to the activation of oncogenes, loss of tumor suppressors, and
the effects of the tumor microenvironment (Cairns et al., 2011).
Hypoxia, a characteristic of most solid tumor microenvironments,
causes a progressive elevation in mitochondrial ROS production
(chronic ROS)which over time leads to the stabilization of cells via
increased HIF-2α expression, which serve as signaling molecules
that activate the transcription of genes involved in cellular hypoxic
adaptation (Hamanaka and Chandel, 2009). It is becoming appar-
ent that hypoxia enables cells to survive with sustained levels
of elevated ROS. However, the increased oxidant concentrations
associated with cellular transformation promote tumorigenicity
through signaling but can also damage DNA, proteins, and lipids.
Indeed, promoting oxidative stress in cancer cells selectively kills
several cancer cell lines (Trachootham et al., 2006; Nogueira et al.,
2008; Ralph et al., 2010).
Reactive oxygen species are mainly produced in the mitochon-
dria as by-products of respiratory chain reactions, with 1–5%
of the oxygen consumed by mitochondria in human cells being
converted to ROS, such as superoxide anions (O−·2 ), H2O2, and
hydroxyl radicals (Murphy, 2009). Oxidative stress results when
production of ROS exceeds the capacity of mitochondrial and cel-
lular anti-oxidant defenses to remove these toxic species. Indeed,
to combat harmful ROS, cells possess several anti-oxidant defense
mechanisms, including catalytic removal of reactive species by
enzymes like superoxide dismutase (SOD), catalase, and peroxi-
dase (Barber et al., 2006; Figure 6). However, about 1% of the ROS
escapes elimination and cause oxidative cellular damage. The rules
governing ROS transport via theOMMand control of this process,
as well as the molecular mechanism of ROS activating VDAC to
release Cyto c, are not clear.
VDAC1 MEDIATES ROS RELEASE FROM THE MITOCHONDRIA
Since ROS are generated in the mitochondria, they can attack the
mitochondria directly and, when released to the cytosol, can attack
and modify DNA, lipids, and proteins, thus affecting cell survival
(Ott et al., 2007). This requires ROS release from the mitochon-
dria to the cytosol, namely, crossing the OMM. VDAC1 in the
OMM may serve as the major gateway for molecules exiting the
IMS. Indeed, VDAC1 has been proposed to mediate ROS release
from the IMS to the cytosol (Figure 6). Several pieces of evidence
support the involvement of VDAC1 in ROS release from the IMS
to the cytosol, including:
(i) HK-I and HK-II bound toVDAC1 decrease ROS release from
mitochondria when over-expressed in HEK cells (Sun et al.,
2008), thereby reducing intracellular levels of ROS (Ahmad
et al., 2002; da-Silva et al., 2004). Also, expression of HK-
I or HK-II was found to protect against oxidant-induced
cell death (Ahmad et al., 2002; Bryson et al., 2002). Thus,
detachment of HK fromVDAC1 could lead to increased ROS
generation and release to the cytoplasm, thereby activating
cell death.
(ii) Closure of VDAC appears to impede the efﬂux of superoxide
anions from the IMS, resulting in an increased steady-state
level of O−·2 , causing internal oxidative stress and sensitiz-
ing mitochondria toward the Ca2+-induced MPT (Tikunov
et al., 2010).
(iii) The VDAC inhibitors, DIDS and dextran sulfate, inhib-
ited O·2 release from the mitochondria to the cytosol (Han
et al., 2003).
ROS-INDUCED APOPTOSIS IS MEDIATED VIA VDAC1
Mitochondria are the major source of ROS that, when released to
the cytosol, can damage proteins, lipids and DNA. ROS release is
mediated via VDAC1, with its interactors (e.g., HK, DIDS, RuR,
AzRu) inhibiting release (Figure 7). Mitochondria also contain
several enzymes that can decompose ROS. ROS can promote Cyto
c release from mitochondria (Petrosillo et al., 2001, 2003). In fact,
it has been shown that apoptosis-inducing agents, such as inor-
ganic arsenic compounds (Shi et al., 2004; Ding et al., 2005) and
doxorubicin (Olson et al., 1981; Sokolove, 1994), cause oxidative
damage to DNA and protein by inducing ROS generation.
Inhibition of O−·2 -induced apoptosis by DIDS, an inhibitor
of VDAC channel activity, or anti-VDAC1 antibodies (Shoshan-
Barmatz et al., 1996; Madesh and Hajnoczky, 2001; Shimizu et al.,
2001; Simamura et al., 2006), suggests that O−·2 -induces Cyto
c release via VDAC-dependent permeabilization of the OMM
(Madesh and Hajnoczky, 2001). Moreover, O−·2 was found to
evoke Cyto c release in VDAC-reconstituted liposomes (Madesh
and Hajnoczky, 2001). In other studies, it was found that ROS-
induced alterations of VDAC1 and/or ANT can induce MMP
selective for Cyto c release, without causing further mitochon-
drial damage (Madesh and Hajnoczky, 2001; Le Bras et al., 2005).
In addition, ROS-induced up-regulation of VDAC1 can be pre-
vented by the ROS chelator, epigallocatechin (Jung et al., 2007). It
has been suggested that ROS-mediated Cyto c and SOD1 release
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FIGURE 7 | Reactive oxygen species occlusion and degradation in
mitochondria can prevent cell damage. A schematic presentation
summarizing current knowledge and proposed control mechanisms for ROS
production, neutralization, and cellular effects (see VDAC1 Function in ROS
Release, ROS-mediated Apoptosis and Interaction with NO). Free radicals
generated by the electron transport chain are generally regarded as toxic
metabolites and, as such, are degraded by specialized enzymes, namely
catalases, peroxidases, superoxide dismutases, and glutathione peroxidase.
Mitochondrial ROS cross the OMM via VDAC. The ROS that escapes catalytic
removal can cause oxidative damage ( ) to mitochondria, and when released
from the mitochondria, can damage cellular proteins, lipids, and DNA. In
addition, ROS can induce apoptosis. ROS is proposed to induce Cyto c
release by oxidizing the mitochondria-speciﬁc phospholipid, cardiolipin (CL).
ROS-oxidized CL has a markedly lower afﬁnity for Cyto c, thus rendering Cyto
c free in the inter-membrane space. ROS can also induce VDAC
oligomerization to yield a mega-channel mediating Cyto c release. VDAC
inhibitors (e.g., RuR, AzRu, DIDS) and hexokinase (HK) can prevent ROS
release to the cytosol. CuZnSOD, cytosolic (copper–zinc-containing)
superoxide dismutases; MnSOD, mitochondrial (manganese-containing)
superoxide dismutases; GPx, glutathione peroxidase.
from mitochondria involves VDAC, leading to increased suscep-
tibility of mitochondria to oxidative stress and apoptosis (Li and
Yuan, 2008).
Interactions between TSPO and VDAC1 are proposed to play
a role in apoptosis (Gavish et al., 1999; Veenman et al., 2004;
Levin et al., 2005; see VDAC and the Translocator Protein). TSPO
appears to be involved in the generation of ROS, leading to apop-
tosis induction (Veenman et al., 2008). It was hypothesized that the
close association of TSPO with VDAC may enhance the concen-
tration of ROS generated by TSPO, leading to apoptosis induction
(Golani et al., 2001; Veenman et al., 2002, 2007).
NITRIC OXIDE, MITOCHONDRIA, VDAC AND CELL DEATH
Nitric oxide (NO) possesses both pro- and anti-apoptotic effects,
depending on both cell type and NO concentration (Brune et al.,
1999; Kim et al., 1999). Speciﬁc NO molecular targets include
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inhibition of Bcl-2 cleavage (Kim et al., 1998) and inactivation of
caspases by S-nitrosylation (Li et al., 1999). At low physiological
release rates, NO was found to inhibit PTP opening in a reversible
manner, while at high physiological release rates, NO acceler-
ated PTP opening (Brookes et al., 2000). VDAC1 was found to
bind the endothelial NO synthase (eNOS; Sun and Liao, 2002).
In vitro binding studies using glutathione S-transferase (GST)-
tagged VDAC1 indicated that VDAC1 binds directly to eNOS
and that this interaction ampliﬁed eNOS activity. Furthermore,
the calcium ionophores, A23187 and bradykinin, both known
to activate eNOS, increased VDAC1–eNOS complex formation,
suggesting a potential role for intracellular Ca2+ in mediating
this interaction (Sun and Liao, 2002). The above results indicate
that the interaction between VDAC and eNOS may be impor-
tant for regulating eNOS activity and modulation of VDAC by
NO (Sun and Liao, 2002). Recently, it has been reported that
exogenous NO directly interacts with puriﬁed VDAC from rat
heart and inhibited its channel activity in a biphasic manner. This
inhibitionwas prevented by aNOscavenger. Channel activity inhi-
bition paralleled the delay in opening of the cardiac PTP by NO
(Cheng et al., 2011).
VDAC1 TRANSPORT OF Ca2+ AND FUNCTION IN
ER–MITOCHONDRIA CROSS-TALK
MITOCHONDRIAL Ca2+ TRANSPORT AND VDAC1
Ca2+ is a ubiquitous cellular signal, with changes in intracellular
Ca2+ concentration not only stimulating a number of intercellular
events but also triggering cell death pathways, including apoptosis.
Ca2+ signals result in the regulation of Ca2+-dependent enzymes,
such as phospholipases, proteases, and nucleases, important dur-
ing injury or cell death (Berridge et al., 2000). Apart from their
metabolic and apoptotic roles, mitochondria are also a major
hub of cellular Ca2+ homeostasis. Indeed, mitochondrial Ca2+
homeostasis is fundamental for a wide range of cellular activities,
such as control of oxidative phosphorylation (Cox and Matlib,
1993; Maack et al., 2006), modulation of cytosolic calcium signals
(Gunter et al., 2000), cell death (Giacomello et al., 2007), and secre-
tion (Maechler et al., 1997; Lee et al., 2003). Intra-mitochondrial
Ca2+ controls energy metabolism by enhancing the rate of
NADH production by modulating critical enzymes, such as those
of the TCA cycle and fatty acid oxidation (Nichols and Denton,
1995; Denton, 2009), linking glycolysis to the TCA cycle (Cárdenas
et al., 2010).
Ca2+ transport across the IMM is mediated by several recently
identiﬁed proteins. The mitochondrial Ca2+ uniporter (MCU;
Baughman et al., 2011; De Stefani et al., 2011), as well as its reg-
ulatory protein, the EF hand-containing protein termed MICU1
(for mitochondrial calcium uptake 1), acting as a Ca2+ sensor
that controls mitochondrial Ca2+ entry mediated by the MCU,
were identiﬁed (Santo-Domingo and Demaurex, 2010). The high-
afﬁnity mitochondrial Ca2+/H+ exchanger, Letm1, is able to
import Ca2+ at low (i.e., sub-micromolar) cytosolic concentra-
tions into energized mitochondria (Jiang et al., 2009), while the
Na+/Ca2+ exchanger superfamily, NCLX, is the major Ca2+ efﬂux
mechanism (Palty et al., 2010). All the Ca2+ transport systems
described above mediate the transport of Ca2+ across the IMM
(Figure 1). However, incomingCa2+ must ﬁrst traverse theOMM.
The only identiﬁed proteinmediatingCa2+ transport in theOMM
is VDAC1. Indeed, VDAC1 is permeable to Ca2+ and possesses
Ca2+-binding sites (Gincel et al., 2001; Rapizzi et al., 2002; Tan
and Colombini, 2007) and it has been shown that control of OMM
Ca2+ permeability is mediated by VDAC (Bathori et al., 2006; Tan
and Colombini, 2007).
Ca2+, MITOCHONDRIA, APOPTOSIS, AND VDAC
Although changes in mitochondrial Ca2+ concentration are
known to trigger apoptosis, the precise mechanism is not known.
VDAC1 is highly Ca2+-permeable and modulates Ca2+ access
to the mitochondrial inter-membrane space (Gincel et al., 2001;
Tan and Colombini, 2007). Non-physiological Ca2+ overload
depolarizes mitochondria by opening the PTP, with concomi-
tant release of Cyto c and other IMS proteins (Crompton, 1999;
Baumgartner et al., 2009) that can lead to both apoptotic and
necrotic cell death, associated with disease pathogenesis (Rasola
and Bernardi, 2011). Thus, Ca2+ overload disrupts energy pro-
duction by mitochondria and enables apoptosis and/or necrosis
(Shoshan-Barmatz and Gincel, 2003; Kinnally et al., 2011; Rasola
and Bernardi, 2011). Ca2+ overload also results in production of
ROS. To date, the mitochondrial target for Ca2+ activation of
Cyto c release has not been identiﬁed. The inhibition of PTP
opening by RuR (Gincel et al., 2001), while protection against
cell death induced by several apoptotic stimuli (Baek et al., 1997;
Ding et al., 2001; Bae et al., 2003) may arise from RuR interac-
tion with VDAC1, inducing channel closure (Gincel et al., 2001).
This is supported by the ﬁndings that E72Q-VDAC1 did not inter-
act with RuR and cells expressing this mutant were not protected
against apoptosis by RuR (Zaid et al., 2005). These observations
suggest that Ca2+-binding sites in VDAC1 (Israelson et al., 2008)
serve regulatory functions, including those involved in apoptosis
induction.
ER–MITOCHONDRIA Ca2+ TRANSPORT, VDAC, AND APOPTOSIS
The ER is a dynamic reservoir of Ca2+ ions with electrical or
chemical cell stimulation resulting in its activation (Bootman et al.,
2002; Verkhratsky and Petersen, 2002), highlighting the role of
this organelle as an indispensable component of Ca2+ signaling
processes. Ca2+ originating from the ER has been shown to be a
potent death-inducing signal (Pinton et al., 2008).
The interplay between ER- and mitochondria-mediated Ca2+
signaling is a determinant of cellular fate through the control of
apoptosis and autophagy (Decuypere et al., 2011). Release of Ca2+
from the ER via inositol-1,4,5-trisphosphate receptors (IP3Rs)
has been observed in models of apoptosis and has been impli-
cated directly in mitochondrial Ca2+ overload (Hajnoczky et al.,
2003). The speciﬁc sites of physical association between the ER and
mitochondria, known as mitochondria-associated membranes
(MAMs), includeVDAC among the proteins present at these junc-
tions (Bononi et al., 2012). The mitochondrial chaperone, grp75
(glucose-regulated protein 75), has been proposed to mediate
the molecular interaction of VDAC1 with the ER Ca2+-release
channel, IP3R, and that chaperone-mediated conformational cou-
pling of these proteins enables better transfer of the Ca2+ ions
from the ER to the mitochondria (Szabadkai et al., 2006). In a
cell-free system containing puriﬁed mitochondria, ER vesicles,
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IP3R, and VDAC1, PTP activity was identiﬁed as being involved
in the ER-triggered pro-apoptotic mitochondrial membrane per-
meabilization process (Deniaud et al., 2008). It has been recently
established that VDAC1 (but not isoforms 2 or 3) selectively inter-
acts with IP3Rs and is preferentially involved in the transmission
of low-amplitude apoptotic Ca2+ signals tomitochondria (De Ste-
fani et al., 2012). The involvement of VDAC1 in ER–mitochondria
Ca2+ cross-talk places VDAC1 at a crucial position on the route
transferring Ca2+ signals from the ER to mitochondria, and thus
couples ER and mitochondrial functions (De Stefani et al., 2012).
VDAC AS A PHARMACOLOGICAL TARGET FOR COMPOUNDS
AFFECTING CELL PROLIFERATION OR APOPTOSIS
VDAC1, as a multi-functional channel involved both in metabolic
homeostasis and apoptosis, can be considered as a prime target
for therapeutic agents designed to act via metabolic interference
or modulating apoptosis (Shoshan-Barmatz and Ben-Hail, 2011;
Shoshan-Barmatz and Golan, 2012). Indeed, several studies iden-
tiﬁed pharmacological agents that targetVDAC as inducing cancer
cell death. These agents can be categorized into the following
groups:
ROS-PRODUCING VDAC-DEPENDENT AGENTS
Reactive oxygen species has been shown to promote Cyto c release
from mitochondria, thereby inducing apoptotic cell death (Pet-
rosillo et al., 2001; Petrosillo et al., 2003) (see VDAC1 Function in
ROS Release, ROS-mediated Apoptosis and Interaction with NO).
Currently known drugs acting via enhancing ROS production
include FNQs, erastin, and As2O3.
Furanonaphthoquinones were proposed to induce caspase-
dependent apoptosis via the production of NADH-dependent
ROS. In HeLa cells, FNQs induce mitochondrial swelling, with
subsequent apoptosis, while radical scavengers and anti-VDAC1
antibodies reduced this effect (Simamura et al., 2008), suggesting
that FNQ-mediated apoptosis is VDAC-dependent. This claim is
further supported by the ﬁndings that the ROS production and the
anti-cancer activity of FNQs were increased upon VDAC1 over-
expression and decreased upon silencing of VDAC1 expression
by siRNA (Simamura et al., 2008). FQNs were found to also up-
regulate the pro-apoptotic proteins, Bad, Bax, and Cyto c, while
down-regulating the anti-apoptotic proteins, Bcl-2, survivin, and
XIAP in A549 cells (Su et al., 2010).
Erastin is a cell-permeable piperazinyl–quinazolinone com-
pound that exhibits oncogene-selective lethality toward cells
harboring activating mutations in the RAS–RAF–MEK signaling
pathway. Erastin treatment in these cells rapidly induces ROS pro-
duction and a non-apoptotic form of cell death (Yagoda et al.,
2007). Knockdown of vdac2 or vdac3 caused resistance to erastin,
suggesting their involvement in themechanismof action of erastin
(Yagoda et al., 2007). It was also reported that RSL5, a com-
pound that has increased lethality in the presence of oncogenic
RAS, and erastin induced VDAC3-dependent cell death (Yang and
Stockwell, 2008). Finally, the erastin analog, PRLX 93936, was
found to bind VDAC2 and VDAC3 using a proteomics approach
(Sahasrabudhe et al., 2008). PRLX 93936 is currently in clinical
Phase I for treatment of solid tumors.
As2O3, a clinically active anti-leukemia agent reported to
inhibit mitochondrial respiratory function, increases ROS gen-
eration, and enhances the activity of other O.−2 producing agents
against cultured leukemia cells and primary leukemia cells isolated
from patients (Pelicano et al., 2003).
CHEMICALS THAT DIRECTLY INTERACT WITH AND MODIFY
VDAC ACTIVITY
Various compounds interact with VDAC to modify its activity
(Table 2). Acrolein (2-propen-1-al), the most reactive of the
α,β-unsaturated aldehydes and a toxic compound (Adams and
Klaidman, 1993) that was proposed to react with DNA and pro-
teins, preferential binds at p53 mutational hotspots to inhibit
DNA repair (Feng et al., 2006). Acrolein is a respiratory irritant
that is generated during cooking and is abundant in the envi-
ronment (Izard and Libermann, 1978). The compound is also
Table 2 | Reagents proposed to act viaVDAC (for details, seeVDAC as a PharmacologicalTarget for Compounds Affecting Cell Proliferation or
Apoptosis).
Agents VDAC-mediated cytotoxic Reference
Avicins Pro-apoptotic plant stress metabolites, target and close VDAC Haridas et al. (2007)
Fluoxetine (Prozac) Anti-depressant induces cell proliferation and cell-line dependent apoptotic modulator.
Interacts directly with VDAC, inhibits PTP opening and apoptosis
Nahon et al. (2005)
Cisplatin Interacts directly with VDAC1 and inhibits PTP opening Castagna et al. (2004),
Yang et al. (2006)
Acrolein α,β-Unsaturated aldehydes, carbonylates VDAC in Alzheimer’s disease Mello et al. (2007)
Erastin Anti-cancer agent that binds directly to VDAC2 to induce cell death Yagoda et al. (2007)
Endostatin Small collagen type XVIII fragment, angiogenesis inhibitor. Interacts with VDAC1,
inducing PTP opening
Yuan et al. (2008)
Oblimersen 18-mer phosphorothioate anti-sense oligonucleotide. Binds directly to VDAC, blocks
channel activity, pro-apoptotic
Tan et al. (2007)
Furanonaphthoquinones Induce caspase-dependent apoptosis. FNQ-mediated apoptosis is VDAC-dependent Simamura et al. (2008)
Geldanamycin 17AAG Binds to VDAC and inhibits cell invasion Xie et al. (2011)
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endogenously generated by lipid peroxidation at sites of injury
(Adams and Klaidman, 1993). In pathological conditions associ-
atedwith oxidative stress (Voulgaridou et al., 2011), like spinal cord
injury (Luo et al., 2005) andAlzheimer’s disease (Dang et al., 2010),
levels of acrolein were found to be elevated. Acrolein is reported
to enhance carbonylation of VDAC, an event that was found to be
signiﬁcantly increased in the brains of Alzheimer’s disease patients
(Mello et al., 2007).
Avicins represents a family of triterpenoid saponins, plant stress
metabolites that exhibit cytotoxic activity in tumor cells. These
compounds possess anti-inﬂammatory and anti-oxidant proper-
ties capable of perturbing mitochondrial function and initiating
apoptosis in tumor cells (Gaikwad et al., 2005;Haridas et al., 2005).
Avicin G reduces VDAC1 channel conductance, ATP levels, and
respiration rates in Jurkat cells (Lemeshko et al., 2006; Haridas
et al., 2007).
Cisplatin (cis-diamminedichloro platinum(II)) is a widely used
anti-cancer drug that trigger apoptosis (Santin et al., 2011). Cis-
platin acts by forming inter- and intra-strand nuclear DNA
cross-links upon binding (Zamarin et al., 2005). Mitochondria,
however, have been implicated as a cisplatin target, leading to
apoptosis induction (Yang et al., 2006; Cullen et al., 2007). Cis-
platin binds to mitochondrial DNA and VDAC (Yang et al., 2006)
to regulate VDAC activity (Castagna et al., 2004). Thus, it was
proposed that VDAC acts as a cisplatin receptor during apoptosis
(Thinnes, 2009). Recently it was suggested that over-expression
of SCIN, a calcium-dependent actin-binding protein, is a novel
cisplatin-resistant marker in the human bladder cancer cell line,
HT1376 (Miura et al., 2012). It was proposed that the high expres-
sion of SCIN and its interaction with VDAC mediates resistance
to cisplatin (Miura et al., 2012).
Endostatin is a naturally occurring 20 kDaC-terminal fragment
derived from type XVIII collagen that may interfere with the pro-
angiogenic action of growth factors (Folkman, 2006). Endostatin
has a wide range of anti-cancer spectrum targets (Karamouzis and
Moschos, 2009). Decreasing VDAC1 levels by siRNA attenuates
endostatin-induced apoptosis, while over-expression of VDAC1
enhances the sensitivity of endothelial cells to endostatin (Yuan
et al., 2008). Endostatinwas found to induce PTPopening through
VDAC1 (Yuan et al., 2008). These ﬁndings point to VDAC1 as
endostatin target.
Fluoxetine (also known as Prozac, Sarafem, Fontex) is an anti-
depressant, acting as a selective serotonin re-uptake inhibitor and
is clinically used to treat different major depressions, obsessive-
compulsive disorder, bulimia nervosa, and panic disorders, among
other psychiatric conditions (Wong et al., 1995). The connection
between ﬂuoxetine and apoptosis is clouded by a series of contra-
dictory ﬁndings. Fluoxetine was reported to enhance apoptosis in
different cancer cells and tumors (Cloonan et al., 2010; Lee et al.,
2010; Frick et al., 2011), yet was suggested to prevent apoptosis in
both cancerous and neuronal cells (Wright et al., 1994; Lee et al.,
2001; Chiou et al., 2006; Wang et al., 2011). Fluoxetine was shown
to interact withVDAC1 and to increase the voltage-dependence of
bilayer-reconstituted VDAC1 (Nahon et al., 2005; Thinnes, 2005).
Additionally, ﬂuoxetine was shown to prevent PTP opening and
inhibited the release of Cyto c and apoptosis (Nahon et al., 2005).
Although its remains unclear as to whether ﬂuoxetine has an anti-
or pro-apoptotic effect, it does seem that the compound mediates
its effect on apoptosis via interactions with VDAC1.
Oblimersen (G3139) is an 18-mer phosphorothioate anti-sense
oligonucleotide being studied as a possible treatment for several
types of cancer, including CLL (Advani et al., 2011), B cell lym-
phoma (Pro et al., 2008), breast cancer (Rom et al., 2009), and
melanoma (Lai et al., 2006). Although oblimersen is designed
to target the initiation codon region of Bcl-2 mRNA, it was
found to directly interact with VDAC1 and reduce its chan-
nel activity (Lai et al., 2006; Tan et al., 2007). Oblimersen is
reported to induce caspase-dependent apoptosis via the intrin-
sic mitochondrial pathway in a Bcl-2-independent mechanism
(Lai et al., 2006).
Geldanamycin (17AAG) is a derivative of the antibiotic,
ansamycin. Geldanamycin binds to a conserved pocket in the
amino-terminal portion of the Hsp90 chaperone protein and
inhibits its function (Isaacs et al., 2003). In vitro, 17AAG acted
as a Ca2+ mitochondrial regulator, increasing intracellular Ca2+
and diminishing the plasma membrane cationic current (Xie
et al., 2011). 17AAG was shown to interact with VDAC through
a hydrophobic interaction that was independent of Hsp90. This
interaction was proposed to mediate inhibition of glioblastoma
cell invasion (Xie et al., 2011).
FINAL PERSPECTIVE
In recent years, we have witnessed a switch in the focus of VDAC
research from channel activity properties and regulation at the
level of puriﬁed protein in yeast and Neurospora to studying its
function in mammalian cell cultures and animal models. Indeed,
a signiﬁcant accumulation of knowledge is now available con-
cerning VDAC1 function in cell life and death. Much has been
learned about VDAC function in regulating metabolite cross-talk
between the mitochondria and rest of the cell, its function in
mitochondria–ER Ca2+ signaling, its function in apoptosis and
its involvement in various maladies from neurodegenerative dis-
eases to cancer. The studies reviewed above have demonstrated
the pivotal roles of mitochondria and VDAC1 in cancer. The dual
functions of VDAC1 in both metabolism and apoptosis, as medi-
ated by the protein alone and regulated by associated polypeptides,
point to VDAC1 as begin a critical target in addressing cancer
therapy.
Although a high-resolution structure was determined for
recombinant VDAC1, many questions concerning the architec-
ture of the channel pore, the location of modulator-binding sites,
the protein regions involved in the control mechanism of VDAC1
oligomerization and how VDAC is regulated to serve its multiple
roles remain unanswered. Likewise, additional studies are required
to investigate whether the increased dependence of cancer cells on
glycolytic metabolism can be exploited therapeutically.
VDAC1 is integral to mitochondrial ATP production as a
metabolite transporter, as the docking site for mitochondrial-
boundHK,and is highly expressed in cancers.VDAC1 is associated
with the mitochondrial pathway of apoptosis, interacting with
over-expressed anti-apoptotic proteins present in cancer and
mediating the actions of some anti-cancer drugs. In addition,
VDAC1 mediates cholesterol transport and distribution in the
mitochondrial membrane, with cancer cells exhibiting several
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fold higher cholesterol levels than do healthy cells. VDAC1 also
functions in ROS production and transport to the cytosol, with
elevated ROS generation being seen in cancer cells. These func-
tions, together with VDAC1 being over-expressed in some cancer
cells, point toVDAC1as being a rational target for thedevelopment
of a new generation of therapeutics.
Delineating the molecular mechanisms underlying the re-
programmed metabolism seen in cancers and their cell survival
strategies, together with increasing understanding of the difﬁ-
culty in targeting signal transduction in tumorswithout signiﬁcant
side-effects, encourages prospects for the development of effec-
tive cancer therapies. Thus, the emergence of targeted therapies
speciﬁcally targeting critical molecules important for cancer cells
may provide promising means of selectively killing these malig-
nant cells. VDAC1 is one such a target. Indeed, various strategies
involving interference RNA to down-regulate VDAC1 expression
levels,VDAC1-based peptides and smallmolecules, such asmethyl
jasmonate, are being considered in this capacity. Finally, the dis-
covery that VDAC plays a role at critical control points during
energy metabolism and in apoptosis points to VDAC as a novel
pharmacologic target for anti-cancer drugs.
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